pubmed_ids
stringlengths 41
6.9k
| questions
stringlengths 13
215
| ground_truth
stringlengths 2
7.79k
|
|---|---|---|
http://www.ncbi.nlm.nih.gov/pubmed/24449200,http://www.ncbi.nlm.nih.gov/pubmed/22291662 | Which is the protein encoded by the human gene GRIK? | Glutamate Receptor Ionotropic Kainate |
http://www.ncbi.nlm.nih.gov/pubmed/22232559,http://www.ncbi.nlm.nih.gov/pubmed/15834418,http://www.ncbi.nlm.nih.gov/pubmed/18562315,http://www.ncbi.nlm.nih.gov/pubmed/16847063,http://www.ncbi.nlm.nih.gov/pubmed/11813001,http://www.ncbi.nlm.nih.gov/pubmed/23314528,http://www.ncbi.nlm.nih.gov/pubmed/23567651 | Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies? | Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinson's disease patients where it mainly accumulates in the Lewy bodiesApproximately 90% of α-syn deposited in Lewy bodies is phosphorylated at serine 129 (Ser129). In contrast, only 4% or less of total α-syn is phosphorylated at this residue in the normal brain. This suggests that the accumulation of Ser129-phosphorylated α-syn leads to the formation of Lewy bodies and dopaminergic neurodegeneration in Parkinson's diseaseAlpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies, which are characteristic pathologic lesions of Parkinson disease.Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinsons disease patients where it mainly accumulates in the Lewy bodiesAlpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinson s disease patients where it mainly accumulates in the Lewy bodies |
http://www.ncbi.nlm.nih.gov/pubmed/16633152,http://www.ncbi.nlm.nih.gov/pubmed/18517289,http://www.ncbi.nlm.nih.gov/pubmed/12215058,http://www.ncbi.nlm.nih.gov/pubmed/9463792,http://www.ncbi.nlm.nih.gov/pubmed/8834412,http://www.ncbi.nlm.nih.gov/pubmed/20175591,http://www.ncbi.nlm.nih.gov/pubmed/17035933,http://www.ncbi.nlm.nih.gov/pubmed/17286545,http://www.ncbi.nlm.nih.gov/pubmed/15089103,http://www.ncbi.nlm.nih.gov/pubmed/18983224,http://www.ncbi.nlm.nih.gov/pubmed/18289149,http://www.ncbi.nlm.nih.gov/pubmed/19803925,http://www.ncbi.nlm.nih.gov/pubmed/12672169,http://www.ncbi.nlm.nih.gov/pubmed/19370564,http://www.ncbi.nlm.nih.gov/pubmed/11420571,http://www.ncbi.nlm.nih.gov/pubmed/9213079,http://www.ncbi.nlm.nih.gov/pubmed/11403977,http://www.ncbi.nlm.nih.gov/pubmed/16098854,http://www.ncbi.nlm.nih.gov/pubmed/11865558,http://www.ncbi.nlm.nih.gov/pubmed/16259535,http://www.ncbi.nlm.nih.gov/pubmed/15385695,http://www.ncbi.nlm.nih.gov/pubmed/15841196,http://www.ncbi.nlm.nih.gov/pubmed/18559957,http://www.ncbi.nlm.nih.gov/pubmed/15139800,http://www.ncbi.nlm.nih.gov/pubmed/19724771 | Is paroxetine effective for treatment of premenstrual dysphoric disorder? | Yes, paroxetine is effective and FDA approved treatment of women with premenstrual dysphoric disorder. A number of well designed clinical trials have confirmed efficacy and safety of both continuous or intermittent regiments of paroxetine for treatment of premenstrual dysphoric disorder. A number of other antidepressants and hormaonal therapies were also shown to be effective and are FDA approved for treatment of women with premenstrual dysphoric disorder. |
http://www.ncbi.nlm.nih.gov/pubmed/10673511,http://www.ncbi.nlm.nih.gov/pubmed/15817350,http://www.ncbi.nlm.nih.gov/pubmed/23086432,http://www.ncbi.nlm.nih.gov/pubmed/18403492,http://www.ncbi.nlm.nih.gov/pubmed/16053669,http://www.ncbi.nlm.nih.gov/pubmed/22086614,http://www.ncbi.nlm.nih.gov/pubmed/11763420,http://www.ncbi.nlm.nih.gov/pubmed/20729242,http://www.ncbi.nlm.nih.gov/pubmed/18661102,http://www.ncbi.nlm.nih.gov/pubmed/15380566,http://www.ncbi.nlm.nih.gov/pubmed/17031553,http://www.ncbi.nlm.nih.gov/pubmed/14654909,http://www.ncbi.nlm.nih.gov/pubmed/15072467,http://www.ncbi.nlm.nih.gov/pubmed/25427949,http://www.ncbi.nlm.nih.gov/pubmed/17031561,http://www.ncbi.nlm.nih.gov/pubmed/21896554,http://www.ncbi.nlm.nih.gov/pubmed/18314417,http://www.ncbi.nlm.nih.gov/pubmed/17465245 | What is known about thalidomide therapy and survival of glioblastoma patients? | Findings regarding clinical value of thalidomide in terms of survival in patients with glioblastoma remain mixed. It has been shown that thalidomide can improve survival of recurrent glioblastoma patients. However, other authors have not confirmed these findings. Furthermore, thalidomide did not improve survival of newly diagnosed glioblastoma and pediatric glioblastoma patients. |
http://www.ncbi.nlm.nih.gov/pubmed/11301401,http://www.ncbi.nlm.nih.gov/pubmed/17191085,http://www.ncbi.nlm.nih.gov/pubmed/12516034,http://www.ncbi.nlm.nih.gov/pubmed/12525513,http://www.ncbi.nlm.nih.gov/pubmed/15023336,http://www.ncbi.nlm.nih.gov/pubmed/20926012,http://www.ncbi.nlm.nih.gov/pubmed/18316578,http://www.ncbi.nlm.nih.gov/pubmed/20739545,http://www.ncbi.nlm.nih.gov/pubmed/15985216,http://www.ncbi.nlm.nih.gov/pubmed/23788612,http://www.ncbi.nlm.nih.gov/pubmed/12857600,http://www.ncbi.nlm.nih.gov/pubmed/15901832,http://www.ncbi.nlm.nih.gov/pubmed/12209972,http://www.ncbi.nlm.nih.gov/pubmed/12209593,http://www.ncbi.nlm.nih.gov/pubmed/18838410,http://www.ncbi.nlm.nih.gov/pubmed/17471348,http://www.ncbi.nlm.nih.gov/pubmed/10599057,http://www.ncbi.nlm.nih.gov/pubmed/21442281,http://www.ncbi.nlm.nih.gov/pubmed/17950364,http://www.ncbi.nlm.nih.gov/pubmed/17003465,http://www.ncbi.nlm.nih.gov/pubmed/21181203,http://www.ncbi.nlm.nih.gov/pubmed/17475706,http://www.ncbi.nlm.nih.gov/pubmed/22212932,http://www.ncbi.nlm.nih.gov/pubmed/9887458,http://www.ncbi.nlm.nih.gov/pubmed/11400342,http://www.ncbi.nlm.nih.gov/pubmed/18483373,http://www.ncbi.nlm.nih.gov/pubmed/19336373,http://www.ncbi.nlm.nih.gov/pubmed/10835101,http://www.ncbi.nlm.nih.gov/pubmed/20594164,http://www.ncbi.nlm.nih.gov/pubmed/15939343,http://www.ncbi.nlm.nih.gov/pubmed/21330475,http://www.ncbi.nlm.nih.gov/pubmed/15739185,http://www.ncbi.nlm.nih.gov/pubmed/15931265,http://www.ncbi.nlm.nih.gov/pubmed/14614021,http://www.ncbi.nlm.nih.gov/pubmed/15831230 | Is endostatin a proangiogenic factor? | No, endostatin is an antiangiogenic factor |
http://www.ncbi.nlm.nih.gov/pubmed/17632395,http://www.ncbi.nlm.nih.gov/pubmed/11136708,http://www.ncbi.nlm.nih.gov/pubmed/11343318,http://www.ncbi.nlm.nih.gov/pubmed/12384783,http://www.ncbi.nlm.nih.gov/pubmed/20543391,http://www.ncbi.nlm.nih.gov/pubmed/23591653,http://www.ncbi.nlm.nih.gov/pubmed/22615788,http://www.ncbi.nlm.nih.gov/pubmed/24551838,http://www.ncbi.nlm.nih.gov/pubmed/25401082,http://www.ncbi.nlm.nih.gov/pubmed/16540873,http://www.ncbi.nlm.nih.gov/pubmed/21983728,http://www.ncbi.nlm.nih.gov/pubmed/17108412,http://www.ncbi.nlm.nih.gov/pubmed/22009847,http://www.ncbi.nlm.nih.gov/pubmed/22002330,http://www.ncbi.nlm.nih.gov/pubmed/18001530,http://www.ncbi.nlm.nih.gov/pubmed/18386809,http://www.ncbi.nlm.nih.gov/pubmed/22992817,http://www.ncbi.nlm.nih.gov/pubmed/21192222,http://www.ncbi.nlm.nih.gov/pubmed/21216876,http://www.ncbi.nlm.nih.gov/pubmed/17534191,http://www.ncbi.nlm.nih.gov/pubmed/22744455,http://www.ncbi.nlm.nih.gov/pubmed/22193623,http://www.ncbi.nlm.nih.gov/pubmed/17785083,http://www.ncbi.nlm.nih.gov/pubmed/18007247,http://www.ncbi.nlm.nih.gov/pubmed/25283277,http://www.ncbi.nlm.nih.gov/pubmed/23453657,http://www.ncbi.nlm.nih.gov/pubmed/15303021,http://www.ncbi.nlm.nih.gov/pubmed/23467837,http://www.ncbi.nlm.nih.gov/pubmed/23038618,http://www.ncbi.nlm.nih.gov/pubmed/10494097,http://www.ncbi.nlm.nih.gov/pubmed/19139660,http://www.ncbi.nlm.nih.gov/pubmed/19212754,http://www.ncbi.nlm.nih.gov/pubmed/24603539,http://www.ncbi.nlm.nih.gov/pubmed/17023856,http://www.ncbi.nlm.nih.gov/pubmed/8180508,http://www.ncbi.nlm.nih.gov/pubmed/21146321,http://www.ncbi.nlm.nih.gov/pubmed/19634821,http://www.ncbi.nlm.nih.gov/pubmed/22278929,http://www.ncbi.nlm.nih.gov/pubmed/21520258,http://www.ncbi.nlm.nih.gov/pubmed/25313366,http://www.ncbi.nlm.nih.gov/pubmed/1345899,http://www.ncbi.nlm.nih.gov/pubmed/12973153,http://www.ncbi.nlm.nih.gov/pubmed/15832907,http://www.ncbi.nlm.nih.gov/pubmed/15457700,http://www.ncbi.nlm.nih.gov/pubmed/15457701,http://www.ncbi.nlm.nih.gov/pubmed/25504735,http://www.ncbi.nlm.nih.gov/pubmed/19340878,http://www.ncbi.nlm.nih.gov/pubmed/18021699,http://www.ncbi.nlm.nih.gov/pubmed/24833718,http://www.ncbi.nlm.nih.gov/pubmed/21308753,http://www.ncbi.nlm.nih.gov/pubmed/21228746,http://www.ncbi.nlm.nih.gov/pubmed/19337134,http://www.ncbi.nlm.nih.gov/pubmed/20627007,http://www.ncbi.nlm.nih.gov/pubmed/17414906,http://www.ncbi.nlm.nih.gov/pubmed/15088139,http://www.ncbi.nlm.nih.gov/pubmed/21691901,http://www.ncbi.nlm.nih.gov/pubmed/2605936,http://www.ncbi.nlm.nih.gov/pubmed/20733416,http://www.ncbi.nlm.nih.gov/pubmed/19192405,http://www.ncbi.nlm.nih.gov/pubmed/9408396,http://www.ncbi.nlm.nih.gov/pubmed/21228692,http://www.ncbi.nlm.nih.gov/pubmed/24469715,http://www.ncbi.nlm.nih.gov/pubmed/10096591,http://www.ncbi.nlm.nih.gov/pubmed/24038971,http://www.ncbi.nlm.nih.gov/pubmed/23096252,http://www.ncbi.nlm.nih.gov/pubmed/20436380,http://www.ncbi.nlm.nih.gov/pubmed/22158057,http://www.ncbi.nlm.nih.gov/pubmed/18794762,http://www.ncbi.nlm.nih.gov/pubmed/17108395,http://www.ncbi.nlm.nih.gov/pubmed/17108398,http://www.ncbi.nlm.nih.gov/pubmed/8982144,http://www.ncbi.nlm.nih.gov/pubmed/25408124,http://www.ncbi.nlm.nih.gov/pubmed/2932368,http://www.ncbi.nlm.nih.gov/pubmed/23259508,http://www.ncbi.nlm.nih.gov/pubmed/23364988,http://www.ncbi.nlm.nih.gov/pubmed/22095884,http://www.ncbi.nlm.nih.gov/pubmed/23812140,http://www.ncbi.nlm.nih.gov/pubmed/18985072,http://www.ncbi.nlm.nih.gov/pubmed/23724359,http://www.ncbi.nlm.nih.gov/pubmed/24023777,http://www.ncbi.nlm.nih.gov/pubmed/17932119,http://www.ncbi.nlm.nih.gov/pubmed/19726741,http://www.ncbi.nlm.nih.gov/pubmed/15717203,http://www.ncbi.nlm.nih.gov/pubmed/19080622,http://www.ncbi.nlm.nih.gov/pubmed/17108457,http://www.ncbi.nlm.nih.gov/pubmed/21740577,http://www.ncbi.nlm.nih.gov/pubmed/22183150,http://www.ncbi.nlm.nih.gov/pubmed/17156628,http://www.ncbi.nlm.nih.gov/pubmed/25005481,http://www.ncbi.nlm.nih.gov/pubmed/25410117,http://www.ncbi.nlm.nih.gov/pubmed/10399127,http://www.ncbi.nlm.nih.gov/pubmed/10466862 | List Genes associated with adolescent idiopathic scoliosis | Exome Sequencing Identifies a Rare HSPG2 Variant Associated with Familial Idiopathic Scoliosis.Overall, these findings demonstrate a novel role for kif6 in spinal development and identify a new candidate gene for human idiopathic scoliosis.No genetic associations have yet been found to adolescent idiopathic scoliosis. |
http://www.ncbi.nlm.nih.gov/pubmed/23735780,http://www.ncbi.nlm.nih.gov/pubmed/24235190 | Can botulism poisoning of a pregnant woman harm her fetus? | Botulinum toxin, which causes botulism, is not expected to be present in systemic circulation following proper intramuscular or intradermal injection. Moreover, botulinum toxin has a high molecular weight, and does not appear to cross the placenta. Based on the study cases reported in the literature, botulism poisoning during pregnancy does not appear to increase the risk of adverse outcome in the fetus. |
http://www.ncbi.nlm.nih.gov/pubmed/22473248,http://www.ncbi.nlm.nih.gov/pubmed/16310120,http://www.ncbi.nlm.nih.gov/pubmed/22136212,http://www.ncbi.nlm.nih.gov/pubmed/20235039,http://www.ncbi.nlm.nih.gov/pubmed/15062207,http://www.ncbi.nlm.nih.gov/pubmed/18330528,http://www.ncbi.nlm.nih.gov/pubmed/18371047,http://www.ncbi.nlm.nih.gov/pubmed/21176430,http://www.ncbi.nlm.nih.gov/pubmed/22712761,http://www.ncbi.nlm.nih.gov/pubmed/23093633,http://www.ncbi.nlm.nih.gov/pubmed/15928960,http://www.ncbi.nlm.nih.gov/pubmed/23425613,http://www.ncbi.nlm.nih.gov/pubmed/18360636,http://www.ncbi.nlm.nih.gov/pubmed/22760463,http://www.ncbi.nlm.nih.gov/pubmed/21077473,http://www.ncbi.nlm.nih.gov/pubmed/21601255,http://www.ncbi.nlm.nih.gov/pubmed/16481094,http://www.ncbi.nlm.nih.gov/pubmed/15291651,http://www.ncbi.nlm.nih.gov/pubmed/15643101 | List the off-label use of SSRIs | depression during childhood and adolescence
Premature ejaculation (PE)
erectile dysfunction
Insomnia
postprostatectomy established stress urinary incontinence.
mood and anxiety disorders during pregnancy and breast feeding
symptoms of vasomotor dysregulation (hot flashes) associated with the menopausal transition and sex hormone deprivation
..off-label uses include the treatment of bulimia, benzodiazepine/alcohol dependence, fibromyalgia, central nervous system degenerative diseases (behavioral disorders in dementia and other organic disorders), schizophrenia, chronic pain disease and diabetic neuropathy, sexual dysfunction. |
http://www.ncbi.nlm.nih.gov/pubmed/16636294,http://www.ncbi.nlm.nih.gov/pubmed/19452047,http://www.ncbi.nlm.nih.gov/pubmed/19833446,http://www.ncbi.nlm.nih.gov/pubmed/16751093,http://www.ncbi.nlm.nih.gov/pubmed/19229130,http://www.ncbi.nlm.nih.gov/pubmed/19052667 | Which is the definition of pyknons in DNA? | Pyknons are non-random sequence patterns significantly repeated throughout non-coding genomic DNA, which have additional nonoverlapping instances in the untranslated and protein-coding regions. They are found more frequently in the 3' untranslated regions of genes than in other regions of the human genome. |
http://www.ncbi.nlm.nih.gov/pubmed/22586276,http://www.ncbi.nlm.nih.gov/pubmed/9516420,http://www.ncbi.nlm.nih.gov/pubmed/22200500,http://www.ncbi.nlm.nih.gov/pubmed/15046982,http://www.ncbi.nlm.nih.gov/pubmed/11471242,http://www.ncbi.nlm.nih.gov/pubmed/18687885,http://www.ncbi.nlm.nih.gov/pubmed/19017647,http://www.ncbi.nlm.nih.gov/pubmed/16342967,http://www.ncbi.nlm.nih.gov/pubmed/11574687,http://www.ncbi.nlm.nih.gov/pubmed/24023978,http://www.ncbi.nlm.nih.gov/pubmed/15050829 | Does a linker histone exist in the yeast genome? | Here, we present our results showing a connection between the linker histones, the higher-order chromatin structures, and the process of chronological lifespan of yeast cells. Characteristically, linker histone depleted chromatin generally exhibited longer chromatin loops than the wild-type. These results suggest that HHO1p may play a similar role to linker histones, but at restricted locations in the chromatin. The binding was structure specific, since the use of double-stranded DNA, or a mutant Hho1p in which the second DNA binding site of globular domain 1 was abolished, resulted in a significant decrease in bridged binding.Hho1p is a bona fide linker histoneIn Saccharomyces cerevisiae, HHO1 encodes a putative linker histone with very significant homology to histone H1. The putative linker histone in Saccharomyces cerevisiae, Hho1p, has two regions of sequence (GI and GII) that are homologous to the single globular domains of linker histones H1 and H5 in higher eukaryotes. |
http://www.ncbi.nlm.nih.gov/pubmed/15247430,http://www.ncbi.nlm.nih.gov/pubmed/19307292,http://www.ncbi.nlm.nih.gov/pubmed/23274303,http://www.ncbi.nlm.nih.gov/pubmed/18056425,http://www.ncbi.nlm.nih.gov/pubmed/23224971,http://www.ncbi.nlm.nih.gov/pubmed/18625844,http://www.ncbi.nlm.nih.gov/pubmed/22614729,http://www.ncbi.nlm.nih.gov/pubmed/22834816,http://www.ncbi.nlm.nih.gov/pubmed/12590136,http://www.ncbi.nlm.nih.gov/pubmed/15475613,http://www.ncbi.nlm.nih.gov/pubmed/21984185,http://www.ncbi.nlm.nih.gov/pubmed/23221646,http://www.ncbi.nlm.nih.gov/pubmed/23388391,http://www.ncbi.nlm.nih.gov/pubmed/22955276,http://www.ncbi.nlm.nih.gov/pubmed/17090538,http://www.ncbi.nlm.nih.gov/pubmed/19111172,http://www.ncbi.nlm.nih.gov/pubmed/18334997,http://www.ncbi.nlm.nih.gov/pubmed/21965533,http://www.ncbi.nlm.nih.gov/pubmed/23496118,http://www.ncbi.nlm.nih.gov/pubmed/14970390,http://www.ncbi.nlm.nih.gov/pubmed/23019593 | What is the role of deadenylases in the cell? | The 3'-poly(A) tail, found on mRNAs, is enzymatically shortened by a process referred to as "deadenylation" which is carried out by deadenylases. Deadenylases are magnesium dependent exoribonucleases that specifically catalyze the degradation of eukaryotic mRNA poly(A) tail in the 3'-->5' direction with the release of 5'-AMP as the product. They consist of three potential RNA-binding domains: the catalytic nuclease domain, the R3H domain and the RRM domain. |
http://www.ncbi.nlm.nih.gov/pubmed/25093016,http://www.ncbi.nlm.nih.gov/pubmed/26422722,http://www.ncbi.nlm.nih.gov/pubmed/24646743,http://www.ncbi.nlm.nih.gov/pubmed/24200404,http://www.ncbi.nlm.nih.gov/pubmed/24552447,http://www.ncbi.nlm.nih.gov/pubmed/24918373,http://www.ncbi.nlm.nih.gov/pubmed/25599143,http://www.ncbi.nlm.nih.gov/pubmed/25713988,http://www.ncbi.nlm.nih.gov/pubmed/25246805,http://www.ncbi.nlm.nih.gov/pubmed/22455412 | What molecule is targeted by brodalumab? | Interleukin-17. Brodalumab is anti interleukin-17 monoclonal antibody. |
http://www.ncbi.nlm.nih.gov/pubmed/11810275,http://www.ncbi.nlm.nih.gov/pubmed/21916613,http://www.ncbi.nlm.nih.gov/pubmed/21637438 | How long, in kb (kilobases), is a "Long interspersed nuclear element"? | The retrotransposon known as long interspersed nuclear element-1 (L1) is 6-7 kb long, |
http://www.ncbi.nlm.nih.gov/pubmed/20442305,http://www.ncbi.nlm.nih.gov/pubmed/9326316,http://www.ncbi.nlm.nih.gov/pubmed/7485153,http://www.ncbi.nlm.nih.gov/pubmed/8528106,http://www.ncbi.nlm.nih.gov/pubmed/8699317,http://www.ncbi.nlm.nih.gov/pubmed/9190537,http://www.ncbi.nlm.nih.gov/pubmed/17573495,http://www.ncbi.nlm.nih.gov/pubmed/17209131,http://www.ncbi.nlm.nih.gov/pubmed/16741618,http://www.ncbi.nlm.nih.gov/pubmed/10973261,http://www.ncbi.nlm.nih.gov/pubmed/16861979,http://www.ncbi.nlm.nih.gov/pubmed/8845843,http://www.ncbi.nlm.nih.gov/pubmed/11257108,http://www.ncbi.nlm.nih.gov/pubmed/10874316,http://www.ncbi.nlm.nih.gov/pubmed/23578956,http://www.ncbi.nlm.nih.gov/pubmed/10712197,http://www.ncbi.nlm.nih.gov/pubmed/9668168,http://www.ncbi.nlm.nih.gov/pubmed/12695655,http://www.ncbi.nlm.nih.gov/pubmed/18196300,http://www.ncbi.nlm.nih.gov/pubmed/8264648,http://www.ncbi.nlm.nih.gov/pubmed/15770836,http://www.ncbi.nlm.nih.gov/pubmed/17019046,http://www.ncbi.nlm.nih.gov/pubmed/17564507,http://www.ncbi.nlm.nih.gov/pubmed/17295913,http://www.ncbi.nlm.nih.gov/pubmed/21354044 | Which is the gene mutated in type 1 neurofibromatosis? | NF1 gene, encoding neurofibromin 1 |
http://www.ncbi.nlm.nih.gov/pubmed/22517378,http://www.ncbi.nlm.nih.gov/pubmed/25486381,http://www.ncbi.nlm.nih.gov/pubmed/23728220,http://www.ncbi.nlm.nih.gov/pubmed/12706360,http://www.ncbi.nlm.nih.gov/pubmed/17896915,http://www.ncbi.nlm.nih.gov/pubmed/23948974,http://www.ncbi.nlm.nih.gov/pubmed/21739168,http://www.ncbi.nlm.nih.gov/pubmed/21049281,http://www.ncbi.nlm.nih.gov/pubmed/18981465,http://www.ncbi.nlm.nih.gov/pubmed/21914576,http://www.ncbi.nlm.nih.gov/pubmed/24328341,http://www.ncbi.nlm.nih.gov/pubmed/23060541,http://www.ncbi.nlm.nih.gov/pubmed/16729916,http://www.ncbi.nlm.nih.gov/pubmed/19929817,http://www.ncbi.nlm.nih.gov/pubmed/24433287,http://www.ncbi.nlm.nih.gov/pubmed/22582818,http://www.ncbi.nlm.nih.gov/pubmed/20648558,http://www.ncbi.nlm.nih.gov/pubmed/17693653,http://www.ncbi.nlm.nih.gov/pubmed/21269250,http://www.ncbi.nlm.nih.gov/pubmed/12154028,http://www.ncbi.nlm.nih.gov/pubmed/24595274,http://www.ncbi.nlm.nih.gov/pubmed/21827415,http://www.ncbi.nlm.nih.gov/pubmed/20029421,http://www.ncbi.nlm.nih.gov/pubmed/21512659,http://www.ncbi.nlm.nih.gov/pubmed/23152080,http://www.ncbi.nlm.nih.gov/pubmed/23229276,http://www.ncbi.nlm.nih.gov/pubmed/18838556,http://www.ncbi.nlm.nih.gov/pubmed/20820929,http://www.ncbi.nlm.nih.gov/pubmed/18779539 | List receptors of the drug Cilengitide | Cilengitide binds αvβ3 and αvβ5 integrins. It inhibits attachment and invasion of malignant cells. Thus, cilengitide is being tested for treatment of cancer patients. |
http://www.ncbi.nlm.nih.gov/pubmed/15328599,http://www.ncbi.nlm.nih.gov/pubmed/21282640,http://www.ncbi.nlm.nih.gov/pubmed/21188497,http://www.ncbi.nlm.nih.gov/pubmed/20803091,http://www.ncbi.nlm.nih.gov/pubmed/18332115,http://www.ncbi.nlm.nih.gov/pubmed/20532223,http://www.ncbi.nlm.nih.gov/pubmed/17594509,http://www.ncbi.nlm.nih.gov/pubmed/19393186,http://www.ncbi.nlm.nih.gov/pubmed/17204284,http://www.ncbi.nlm.nih.gov/pubmed/23374342,http://www.ncbi.nlm.nih.gov/pubmed/15099521,http://www.ncbi.nlm.nih.gov/pubmed/18047649,http://www.ncbi.nlm.nih.gov/pubmed/19324900,http://www.ncbi.nlm.nih.gov/pubmed/15901843,http://www.ncbi.nlm.nih.gov/pubmed/16027113,http://www.ncbi.nlm.nih.gov/pubmed/23303787,http://www.ncbi.nlm.nih.gov/pubmed/12764196 | Can protein coding exons originate from ALU sequences? | Yes. Intronic ALUs can evolve into exons by the activation of splice signals residing within the ALU sequence. While most ALU exons do not add or modify the coding capacity of the resulting transcript, examples have been identified of ALU exons becoming protein coding. |
http://www.ncbi.nlm.nih.gov/pubmed/22362925,http://www.ncbi.nlm.nih.gov/pubmed/22968481,http://www.ncbi.nlm.nih.gov/pubmed/20869034,http://www.ncbi.nlm.nih.gov/pubmed/19219028,http://www.ncbi.nlm.nih.gov/pubmed/22454066,http://www.ncbi.nlm.nih.gov/pubmed/22454067,http://www.ncbi.nlm.nih.gov/pubmed/21520335,http://www.ncbi.nlm.nih.gov/pubmed/21326217 | How could U1 small nuclear RNA be used in therapeutics? | Until now, two main types of therapeutic strategies have been developed using U1 small nuclear RNA (snRNA): 1) Production of a defective, but partially functional protein, with the help of exon skipping, through modulation of pre-mRNA splicing, and 2) Correction of pathogenic effects of splice donor site mutations with the use of U1 snRNA adapted to the defective variant. |
http://www.ncbi.nlm.nih.gov/pubmed/21738055,http://www.ncbi.nlm.nih.gov/pubmed/16309337,http://www.ncbi.nlm.nih.gov/pubmed/22521158 | What is the influence of patent expiry on ACE inhibitor prescribing. | Patent expiry has different effects on prescribing in different systems. It leads to decreased cost but no decreased refill compliance in countries like Sweden, Germany etc. In countries like Taiwan, where doctors profit directly from dispensing, patients are switched to ARBs which are more costly. |
http://www.ncbi.nlm.nih.gov/pubmed/22098224,http://www.ncbi.nlm.nih.gov/pubmed/22223578,http://www.ncbi.nlm.nih.gov/pubmed/17617941,http://www.ncbi.nlm.nih.gov/pubmed/21755327,http://www.ncbi.nlm.nih.gov/pubmed/24392102 | Is there evidence that tomato juice lowers cholesterol levels? | Yes, there is evidence to suggest that tomato juice (and other tomato products) can decrease cholesterol concentrations. It was shown that tomatoes inhibit cholesterol biosynthesis. |
http://www.ncbi.nlm.nih.gov/pubmed/18093339,http://www.ncbi.nlm.nih.gov/pubmed/16365385,http://www.ncbi.nlm.nih.gov/pubmed/21515576 | Are there transposon-free regions in mammalian genomes? | Yes. Despite the presence of over 3 million transposons separated on average by approximately 500 bp, the human and mouse genomes each contain almost 1000 transposon-free regions (TFRs) over 10 kb in length. The majority of human TFRs correlate with orthologous TFRs in the mouse, despite the fact that most transposons are lineage specific. Many human TFRs also overlap with orthologous TFRs in the marsupial opossum, indicating that these regions have remained refractory to transposon insertion for long evolutionary periods. Over 90% of the bases covered by TFRs are noncoding, much of which is not highly conserved. Most TFRs are not associated with unusual nucleotide composition, but are significantly associated with genes encoding developmental regulators, suggesting that they represent extended regions of regulatory information that are largely unable to tolerate insertions, a conclusion difficult to reconcile with current conceptions of gene regulation. |
http://www.ncbi.nlm.nih.gov/pubmed/26121403,http://www.ncbi.nlm.nih.gov/pubmed/24768686,http://www.ncbi.nlm.nih.gov/pubmed/25469751,http://www.ncbi.nlm.nih.gov/pubmed/24480744,http://www.ncbi.nlm.nih.gov/pubmed/25378335,http://www.ncbi.nlm.nih.gov/pubmed/26458103,http://www.ncbi.nlm.nih.gov/pubmed/25430002 | Are messenger RNA molecules epigenetically methylated? | Yes, methyltranscriptome is an exciting new area that studies the mechanisms and functions of methylation in transcripts. |
http://www.ncbi.nlm.nih.gov/pubmed/19367498,http://www.ncbi.nlm.nih.gov/pubmed/10803511,http://www.ncbi.nlm.nih.gov/pubmed/21642962,http://www.ncbi.nlm.nih.gov/pubmed/22158541,http://www.ncbi.nlm.nih.gov/pubmed/22150006,http://www.ncbi.nlm.nih.gov/pubmed/22675518 | Which genes are more frequently affected by somatic mutations in Chronic Lymphocytic Leukemia | TP53, ATM, NOTCH1, XPO1, MYD88, KLHL6, SF3B1, ZMYM3, MAPK1, FBXW7 and DDX3X |
http://www.ncbi.nlm.nih.gov/pubmed/11022098,http://www.ncbi.nlm.nih.gov/pubmed/22042118,http://www.ncbi.nlm.nih.gov/pubmed/22230748,http://www.ncbi.nlm.nih.gov/pubmed/23369287,http://www.ncbi.nlm.nih.gov/pubmed/23684423,http://www.ncbi.nlm.nih.gov/pubmed/11570584,http://www.ncbi.nlm.nih.gov/pubmed/17986000,http://www.ncbi.nlm.nih.gov/pubmed/18684638,http://www.ncbi.nlm.nih.gov/pubmed/20811715,http://www.ncbi.nlm.nih.gov/pubmed/21895989,http://www.ncbi.nlm.nih.gov/pubmed/16221071,http://www.ncbi.nlm.nih.gov/pubmed/19968878 | How effective is the dentritic cells treatment on cancer? | Another approach to cancer therapy takes advantage of the normal role of the dendritic cell as an immune educator. Dendritic cells grab antigens from viruses, bacteria, or other organisms and wave them at T cells to recruit their help in an initial T cell immune response. This works well against foreign cells that enter the body, but cancer cells often evade the self/non-self detection system. By modifying dendritic cells, researchers are able to trigger a special kind of autoimmune response that includes a T cell attack of the cancer cells. Because a cancer antigen alone is not enough to rally the immune troops, scientists first fuse a cytokine to a tumor antigen with the hope that this will send a strong antigenic signal. Next, they grow a patient's dendritic cells in the incubator and let them take up this fused cytokine-tumor antigen. This enables the dendritic cells to mature and eventually display the same tumor antigens as appear on the patient's cancer cells. When these special mature dendritic cells are given back to the patient, they wave their newly acquired tumor antigens at the patient's immune system, and those T cells that can respond mount an attack on the patient's cancer cells. |
http://www.ncbi.nlm.nih.gov/pubmed/17846275,http://www.ncbi.nlm.nih.gov/pubmed/2213842,http://www.ncbi.nlm.nih.gov/pubmed/15336686 | What is the mode of inheritance of nemaline myopathy? | Nemaline myopathy has a autosomal dominant or recessive mode of inheritance. |
http://www.ncbi.nlm.nih.gov/pubmed/24630051,http://www.ncbi.nlm.nih.gov/pubmed/20949524,http://www.ncbi.nlm.nih.gov/pubmed/24035762,http://www.ncbi.nlm.nih.gov/pubmed/25044251 | Which syndrome is NHE6 associated with? | Mutations in the solute carrier family 9, subfamily A member 6 (SLC9A6) gene, encoding the endosomal Na+/H+ exchanger 6 (NHE6) are associated with Christianson syndrome, a syndromic form of X-linked intellectual disability characterized by microcephaly, severe global developmental delay, autistic behavior, early onset seizures and ataxia. |
http://www.ncbi.nlm.nih.gov/pubmed/20608882,http://www.ncbi.nlm.nih.gov/pubmed/22554140,http://www.ncbi.nlm.nih.gov/pubmed/10718038,http://www.ncbi.nlm.nih.gov/pubmed/23231890,http://www.ncbi.nlm.nih.gov/pubmed/12442853,http://www.ncbi.nlm.nih.gov/pubmed/12119585,http://www.ncbi.nlm.nih.gov/pubmed/14769012,http://www.ncbi.nlm.nih.gov/pubmed/19715380,http://www.ncbi.nlm.nih.gov/pubmed/21073206,http://www.ncbi.nlm.nih.gov/pubmed/10858175,http://www.ncbi.nlm.nih.gov/pubmed/14769010,http://www.ncbi.nlm.nih.gov/pubmed/16194131,http://www.ncbi.nlm.nih.gov/pubmed/10345973 | What is known about the reimbursement of Viagra | Coverage of Viagra/Sildenafil for erectile dysfunction by health insurance plans is a contentious issue in developed countries. There are data of the limitations (6 per month) and co-payments (26.6%) by patients in the US.
The costs for Viagra/Sildenafil for PAH (pulmonary artery hypertension) appear to be covered by health insurances in the US. |
http://www.ncbi.nlm.nih.gov/pubmed/21133379,http://www.ncbi.nlm.nih.gov/pubmed/22941912,http://www.ncbi.nlm.nih.gov/pubmed/21953191,http://www.ncbi.nlm.nih.gov/pubmed/16249172,http://www.ncbi.nlm.nih.gov/pubmed/16478717 | Why is lock mass used in Orbitrap measurements? | The lock mass is a compound of known mass and is used to compensate for drifts in instrument calibration. |
http://www.ncbi.nlm.nih.gov/pubmed/19725597,http://www.ncbi.nlm.nih.gov/pubmed/9814660,http://www.ncbi.nlm.nih.gov/pubmed/11772283,http://www.ncbi.nlm.nih.gov/pubmed/11154213 | Which virus is Cidofovir (Vistide) indicated for? | Cidofovir is commonly used in the treatment of cytomegalovirus (CMV) infection and disease. |
http://www.ncbi.nlm.nih.gov/pubmed/17145736,http://www.ncbi.nlm.nih.gov/pubmed/11984521,http://www.ncbi.nlm.nih.gov/pubmed/20004202,http://www.ncbi.nlm.nih.gov/pubmed/24500617,http://www.ncbi.nlm.nih.gov/pubmed/18841702,http://www.ncbi.nlm.nih.gov/pubmed/24959425,http://www.ncbi.nlm.nih.gov/pubmed/16127016,http://www.ncbi.nlm.nih.gov/pubmed/16954804,http://www.ncbi.nlm.nih.gov/pubmed/21426337,http://www.ncbi.nlm.nih.gov/pubmed/21278760,http://www.ncbi.nlm.nih.gov/pubmed/12906096,http://www.ncbi.nlm.nih.gov/pubmed/2765093 | Have gnotobiotic animal models been used for the study of bowel disease? | Yes, gnotobiotic animals (e.g. mice) have been used for the study of bowel disease (e.g. inflammatory bowel disease). |
http://www.ncbi.nlm.nih.gov/pubmed/15742475,http://www.ncbi.nlm.nih.gov/pubmed/2798270,http://www.ncbi.nlm.nih.gov/pubmed/24359474,http://www.ncbi.nlm.nih.gov/pubmed/324229,http://www.ncbi.nlm.nih.gov/pubmed/17103432,http://www.ncbi.nlm.nih.gov/pubmed/23620759,http://www.ncbi.nlm.nih.gov/pubmed/20101707,http://www.ncbi.nlm.nih.gov/pubmed/6548367,http://www.ncbi.nlm.nih.gov/pubmed/2130777,http://www.ncbi.nlm.nih.gov/pubmed/20571508,http://www.ncbi.nlm.nih.gov/pubmed/11754060,http://www.ncbi.nlm.nih.gov/pubmed/23476832,http://www.ncbi.nlm.nih.gov/pubmed/23942271,http://www.ncbi.nlm.nih.gov/pubmed/17190989 | List chromosomes that have been linked to Arnold Chiari syndrome in the literature. | Chromosomes 1, 3, 5, 6, 8, 9, 12, 13, 15, 16, 18, 22, X and Y have been reported in association with Arnold Chiari syndrome in genetic linkage studies and individual case reports. |
http://www.ncbi.nlm.nih.gov/pubmed/22266186,http://www.ncbi.nlm.nih.gov/pubmed/10030577,http://www.ncbi.nlm.nih.gov/pubmed/24974828,http://www.ncbi.nlm.nih.gov/pubmed/24124617,http://www.ncbi.nlm.nih.gov/pubmed/22742646,http://www.ncbi.nlm.nih.gov/pubmed/23145994,http://www.ncbi.nlm.nih.gov/pubmed/16864960,http://www.ncbi.nlm.nih.gov/pubmed/21942527,http://www.ncbi.nlm.nih.gov/pubmed/16083345,http://www.ncbi.nlm.nih.gov/pubmed/15919668,http://www.ncbi.nlm.nih.gov/pubmed/21653923,http://www.ncbi.nlm.nih.gov/pubmed/18971581,http://www.ncbi.nlm.nih.gov/pubmed/15274413,http://www.ncbi.nlm.nih.gov/pubmed/6416622,http://www.ncbi.nlm.nih.gov/pubmed/25401475,http://www.ncbi.nlm.nih.gov/pubmed/22240531,http://www.ncbi.nlm.nih.gov/pubmed/8644855,http://www.ncbi.nlm.nih.gov/pubmed/21422656 | Which translocation is the hallmark of Ewing sarcoma? | Tumours defined as Ewing sarcoma (ES) constitute a group of highly malignant neoplasms that most often affect children and young adults in the first 2 decades of life. The EWS/Fli-1 fusion gene, a product of the translocation t(11;22) (q24; 12), is detected in 95% of ES patientsThe EWS/Fli-1 fusion gene, a product of the translocation t(11;22) (q24;12), is detected in 95% of Ewing sarcoma patients.The hallmark of Ewing s sarcoma (EWS) is a translocation--t(11;22)(q24;q12)--that most frequently results in the EWS/FLI1 aberrant chimeric gene |
http://www.ncbi.nlm.nih.gov/pubmed/19662202 | Is invasion and metastasis one of the hallmarks of cancer? | Yes, invasion and metastasis are one of the so-called hallmarks of cancer. |
http://www.ncbi.nlm.nih.gov/pubmed/22930255,http://www.ncbi.nlm.nih.gov/pubmed/14719083,http://www.ncbi.nlm.nih.gov/pubmed/18425079,http://www.ncbi.nlm.nih.gov/pubmed/16360419,http://www.ncbi.nlm.nih.gov/pubmed/18376799,http://www.ncbi.nlm.nih.gov/pubmed/17382535,http://www.ncbi.nlm.nih.gov/pubmed/15195112,http://www.ncbi.nlm.nih.gov/pubmed/15990723,http://www.ncbi.nlm.nih.gov/pubmed/18856066,http://www.ncbi.nlm.nih.gov/pubmed/12671708,http://www.ncbi.nlm.nih.gov/pubmed/15138808,http://www.ncbi.nlm.nih.gov/pubmed/17611626,http://www.ncbi.nlm.nih.gov/pubmed/17204284,http://www.ncbi.nlm.nih.gov/pubmed/17163847,http://www.ncbi.nlm.nih.gov/pubmed/23132836,http://www.ncbi.nlm.nih.gov/pubmed/20520718,http://www.ncbi.nlm.nih.gov/pubmed/16619249,http://www.ncbi.nlm.nih.gov/pubmed/21371446,http://www.ncbi.nlm.nih.gov/pubmed/20514400,http://www.ncbi.nlm.nih.gov/pubmed/10626797 | Is it possible to detect survivin protein expression in normal human adult tissues? | No. Survivin is an inhibitor of apoptosis that is undetectable in normal differentiated tissues of adult human.Most normal adult tissues do not express survivin, thymus and testis are the only exceptions. |
http://www.ncbi.nlm.nih.gov/pubmed/24962423,http://www.ncbi.nlm.nih.gov/pubmed/23328144,http://www.ncbi.nlm.nih.gov/pubmed/25469326,http://www.ncbi.nlm.nih.gov/pubmed/24490014,http://www.ncbi.nlm.nih.gov/pubmed/26046039 | List symptoms of Meigs' Syndrome. | Meigs' syndrome is a benign ovarian tumor associated with ascites and pleural effusion. |
http://www.ncbi.nlm.nih.gov/pubmed/17264115,http://www.ncbi.nlm.nih.gov/pubmed/16778892,http://www.ncbi.nlm.nih.gov/pubmed/11745432,http://www.ncbi.nlm.nih.gov/pubmed/10692488,http://www.ncbi.nlm.nih.gov/pubmed/12024010,http://www.ncbi.nlm.nih.gov/pubmed/10850408,http://www.ncbi.nlm.nih.gov/pubmed/9178888,http://www.ncbi.nlm.nih.gov/pubmed/9801297,http://www.ncbi.nlm.nih.gov/pubmed/12894594 | What is the effect of CRD-BP on the stability of c-myc mRNA? | The c-myc mRNA coding region determinant-binding protein (CRD-BP) has high affinity for the coding region determinant (CRD) of c-myc mRNA. Such affinity is believed to protect c-myc CRD from endonucleolytic attack.The coding region determinant-binding protein (CRD-BP) binds in vitro to c-myc mRNA and is thought to stabilize the mRNA and increase c-Myc protein abundance |
http://www.ncbi.nlm.nih.gov/pubmed/1432387,http://www.ncbi.nlm.nih.gov/pubmed/23416947,http://www.ncbi.nlm.nih.gov/pubmed/10075890,http://www.ncbi.nlm.nih.gov/pubmed/1821628,http://www.ncbi.nlm.nih.gov/pubmed/20685815,http://www.ncbi.nlm.nih.gov/pubmed/3273186,http://www.ncbi.nlm.nih.gov/pubmed/1445915,http://www.ncbi.nlm.nih.gov/pubmed/6504703,http://www.ncbi.nlm.nih.gov/pubmed/367436 | What is the molecular function of psoralen photobinding on DNA? | The interaction of two water-soluble furocoumarins, 8-(omega-diethyl aminopropyloxy)psoralen hydrochloride (I) and its 5-isomer (II), with DNA has been investigated by spectroscopic, equilibrium dialysis, hydrodynamic and chiroptical techniques. Both compounds intercalate into the polynucleotide double helix. |
http://www.ncbi.nlm.nih.gov/pubmed/17327733,http://www.ncbi.nlm.nih.gov/pubmed/19318112,http://www.ncbi.nlm.nih.gov/pubmed/23326789,http://www.ncbi.nlm.nih.gov/pubmed/17418038,http://www.ncbi.nlm.nih.gov/pubmed/18447940,http://www.ncbi.nlm.nih.gov/pubmed/19401954,http://www.ncbi.nlm.nih.gov/pubmed/22033509,http://www.ncbi.nlm.nih.gov/pubmed/24241345,http://www.ncbi.nlm.nih.gov/pubmed/19660659,http://www.ncbi.nlm.nih.gov/pubmed/17011666,http://www.ncbi.nlm.nih.gov/pubmed/22570859,http://www.ncbi.nlm.nih.gov/pubmed/25493974,http://www.ncbi.nlm.nih.gov/pubmed/21249708,http://www.ncbi.nlm.nih.gov/pubmed/25493978,http://www.ncbi.nlm.nih.gov/pubmed/23076947,http://www.ncbi.nlm.nih.gov/pubmed/18522765,http://www.ncbi.nlm.nih.gov/pubmed/17933428,http://www.ncbi.nlm.nih.gov/pubmed/22626570,http://www.ncbi.nlm.nih.gov/pubmed/22668124,http://www.ncbi.nlm.nih.gov/pubmed/24900479,http://www.ncbi.nlm.nih.gov/pubmed/20486864,http://www.ncbi.nlm.nih.gov/pubmed/23871679,http://www.ncbi.nlm.nih.gov/pubmed/22300914,http://www.ncbi.nlm.nih.gov/pubmed/17588708,http://www.ncbi.nlm.nih.gov/pubmed/24205899,http://www.ncbi.nlm.nih.gov/pubmed/19394357,http://www.ncbi.nlm.nih.gov/pubmed/21497181 | Is progesterone effective for treatment of patients with traumatic brain injury based on clinical trial data? | No. Progesterone has been associated with robust positive effects in animal models of traumatic brain injury (TBI) and with clinical benefits in two phase 2 randomized, controlled trials. However, a recent large clinical trial showed no clinical benefit of progesterone in patients with severe TBI. These data stand in contrast to the robust preclinical data and results of early single-center trials that provided the impetus to initiate phase 3 trials. |
http://www.ncbi.nlm.nih.gov/pubmed/19412431,http://www.ncbi.nlm.nih.gov/pubmed/22017589 | Is there a role for the cylindromatosis tumor suppressor (CYLD) in lung cancer? | To explore a correlation between CYLD expression and responsiveness to TRAIL in lung cancer cell lines, we established lung cancer cell lines that stably express CYLD. Our data provided the first evidence that increased expression of CYLD directly blocks TRAIL-induced NF - B activation, and consequently increases TRAIL-induced apoptosis in lung cancer cells. CYLD may act as a therapeutic target of lung cancer. Targeting CYLD, in combination with TRAIL, may be a new strategy to treat lung cancer with high NF - B activity. Cyld encodes a 956-amino acid deubiquitinating enzyme, which is a negative regulator of nuclear factor kappaB and mitogen-activated protein kinase pathways. Mutations that truncate and inactivate the carboxyl-terminal deubiquitinating domain of CYLD underlie the development of skin appendage tumors in humans, whereas down-regulation of Cyld expression has been associated with the development of various types of human malignancies including lung cancer. To establish an animal model of human CYLD inactivation and characterize the biological role of CYLD in vivo, we generated mice carrying a homozygous deletion of Cyld exon 9 mice ) using a conditional approach. Our study identifies an important role of CYLD in lung maturation, which may underlie the development of many cases of lung cancer. To explore a correlation between CYLD expression and responsiveness to TRAIL in lung cancer cell lines, we established lung cancer cell lines that stably express CYLD. Our data provided the first evidence that increased expression of CYLD directly blocks TRAIL-induced NF - B activation, and consequently increases TRAIL-induced apoptosis in lung cancer cells. But studies have demonstrated that many tumor cells were resistant to TRAIL-induced apoptosis. CYLD is recognized as a negative regulator of nuclear factor-kappa B activity. Cyld encodes a 956-amino acid deubiquitinating enzyme, which is a negative regulator of nuclear factor kappaB and mitogen-activated protein kinase pathways. Mutations that truncate and inactivate the carboxyl-terminal deubiquitinating domain of CYLD underlie the development of skin appendage tumors in humans, whereas down-regulation of Cyld expression has been associated with the development of various types of human malignancies including lung cancer. To establish an animal model of human CYLD inactivation and characterize the biological role of CYLD in vivo, we generated mice carrying a homozygous deletion of Cyld exon 9 mice ) using a conditional approach. Our study identifies an important role of CYLD in lung maturation, which may underlie the development of many cases of lung cancer. Yes. Down-regulation of Cyld expression has been associated with the development of various types of human malignancies including lung cancer. Deletion of exon 9 would cause a carboxyl-terminal truncation of CYLD and inactivation of its deubiquitinating activity. Fibroblasts from Cyld(Delta 9/Delta 9) embryos had hyperactive nuclear factor kappaB and c-Jun kinase pathways compared with control fibroblasts. Cyld(Delta 9/Delta 9) newborn mice were smaller than wild-type littermates with a short and kinky tail and no major developmental defects. However, Cyld(Delta 9/Delta 9) mice died shortly after birth from apparent respiratory dysfunction. Histological examination of E18.5 Cyld(Delta 9/Delta 9) lungs demonstrated an immature phenotype characterized by hyperplasic mesenchyme but apparently normal epithelial, smooth muscle and endothelial structures. Thus, it is thought that CYLD has an important role in lung maturation, which may underlie the development of many cases of lung cancer. |
http://www.ncbi.nlm.nih.gov/pubmed/23526674,http://www.ncbi.nlm.nih.gov/pubmed/22797727,http://www.ncbi.nlm.nih.gov/pubmed/2510609,http://www.ncbi.nlm.nih.gov/pubmed/23097569,http://www.ncbi.nlm.nih.gov/pubmed/20978142,http://www.ncbi.nlm.nih.gov/pubmed/22257305,http://www.ncbi.nlm.nih.gov/pubmed/23194995,http://www.ncbi.nlm.nih.gov/pubmed/23952327,http://www.ncbi.nlm.nih.gov/pubmed/23449218,http://www.ncbi.nlm.nih.gov/pubmed/22973348,http://www.ncbi.nlm.nih.gov/pubmed/23106053,http://www.ncbi.nlm.nih.gov/pubmed/23650931,http://www.ncbi.nlm.nih.gov/pubmed/23521456 | Which medical diagnostic tests are used to test kidney function? | Most common tests used in diagnosing normal kidney function include blood tests such as serum creatinine levels, glomerular filtration rate (GFR) and blood urea nitrogen (BUN) levels, also medical imaging tests like ultrasound and CT Scan. Additionally kidney biopsy is used in more direct but invasive approach. Lastly, and probably the most relevant tests to kidney function are urine tests along the lines of urinalysis, urine protein levels and microalbuminuria creatinine clearance. |
http://www.ncbi.nlm.nih.gov/pubmed/11005264,http://www.ncbi.nlm.nih.gov/pubmed/10867800,http://www.ncbi.nlm.nih.gov/pubmed/15854770,http://www.ncbi.nlm.nih.gov/pubmed/19272424,http://www.ncbi.nlm.nih.gov/pubmed/22370907,http://www.ncbi.nlm.nih.gov/pubmed/9600226,http://www.ncbi.nlm.nih.gov/pubmed/12536227,http://www.ncbi.nlm.nih.gov/pubmed/16691119,http://www.ncbi.nlm.nih.gov/pubmed/10787032,http://www.ncbi.nlm.nih.gov/pubmed/9759660,http://www.ncbi.nlm.nih.gov/pubmed/10822429,http://www.ncbi.nlm.nih.gov/pubmed/10967182,http://www.ncbi.nlm.nih.gov/pubmed/11207422,http://www.ncbi.nlm.nih.gov/pubmed/12722831 | Against which protein is the antibody used for immonostaining of Lewy bodies raised? | alpha-Synuclein is a presynaptic protein, which was identified as a specific component of Lewy bodies (LB) and Lewy neurites. Therefore, immunostaining for detecting the presence of Lewy bodies is carried out using antibodies against alpha-synuclein. |
http://www.ncbi.nlm.nih.gov/pubmed/20932506,http://www.ncbi.nlm.nih.gov/pubmed/22378220,http://www.ncbi.nlm.nih.gov/pubmed/14626795,http://www.ncbi.nlm.nih.gov/pubmed/9664617,http://www.ncbi.nlm.nih.gov/pubmed/10364670,http://www.ncbi.nlm.nih.gov/pubmed/22990134,http://www.ncbi.nlm.nih.gov/pubmed/17364293,http://www.ncbi.nlm.nih.gov/pubmed/18577682,http://www.ncbi.nlm.nih.gov/pubmed/14663844,http://www.ncbi.nlm.nih.gov/pubmed/7474061,http://www.ncbi.nlm.nih.gov/pubmed/21606744,http://www.ncbi.nlm.nih.gov/pubmed/11169342,http://www.ncbi.nlm.nih.gov/pubmed/1415421,http://www.ncbi.nlm.nih.gov/pubmed/10550877,http://www.ncbi.nlm.nih.gov/pubmed/8633653,http://www.ncbi.nlm.nih.gov/pubmed/10590441,http://www.ncbi.nlm.nih.gov/pubmed/8142051,http://www.ncbi.nlm.nih.gov/pubmed/8538346,http://www.ncbi.nlm.nih.gov/pubmed/11717628,http://www.ncbi.nlm.nih.gov/pubmed/10912967,http://www.ncbi.nlm.nih.gov/pubmed/18254450,http://www.ncbi.nlm.nih.gov/pubmed/20059439,http://www.ncbi.nlm.nih.gov/pubmed/12835583,http://www.ncbi.nlm.nih.gov/pubmed/19921962,http://www.ncbi.nlm.nih.gov/pubmed/10419606,http://www.ncbi.nlm.nih.gov/pubmed/18417974,http://www.ncbi.nlm.nih.gov/pubmed/22589170 | Which are the main causes of fetal echogenic bowel? | Fetal echogenic bowel is mainly associated to feto-maternal, intramniotic bleeding but in several cases it is linked to cystic fibrosis, cytomegalovirus (CMV), herpes simplex virus and other viral infections and fetal aneuploidy.Fetal echogenic bowel (FEB) is a soft marker found on second trimester sonography. (PMID: 22990134) A disorder was diagnosed in 32.2% of the fetuses, cystic fibrosis being the most commonly identified (7.6%). We also found digestive malformations (7.0%), chromosomal abnormalities (3.7%), and maternofetal infections (3.7%). (PMID: 20932506) Brightly echogenic bowel in the second trimester was found to be associated with a significant risk of fetal aneuploidy. (PMID: 1415421) echogenic bowel does not uniformly herald an abnormal outcome. Echogenic bowel coexistent with other abnormalities (such as growth deficiency or structural malformations) may be a comarker for aneuploidy. (PMID: 8142051) 112 cases (57%) had a known etiology, which included chromosomal abnormality (7%), infection (4%), cystic fibrosis (1.5%), bowel abnormality (3%), bleeding or stained amniotic fluid (11%), Doppler abnormality (14%), malformation (16%) and miscellaneous (0.5%) (PMID: 12835583) |
http://www.ncbi.nlm.nih.gov/pubmed/20167841,http://www.ncbi.nlm.nih.gov/pubmed/20383170,http://www.ncbi.nlm.nih.gov/pubmed/19546072,http://www.ncbi.nlm.nih.gov/pubmed/15616764 | How does trimetazidine affect intracellular kinase signaling in the heart? | Trimetazidine activates AMPK in diabetic myocardium. Trimetazidine when administered before reperfusion results in activation of p38 mitogen-activated protein kinase and Akt signaling. Trimetazidine when administered during reperfusion does not affect p38MAPK and JNK activation. |
http://www.ncbi.nlm.nih.gov/pubmed/15998640,http://www.ncbi.nlm.nih.gov/pubmed/23086420,http://www.ncbi.nlm.nih.gov/pubmed/12646134,http://www.ncbi.nlm.nih.gov/pubmed/21372139,http://www.ncbi.nlm.nih.gov/pubmed/22578719,http://www.ncbi.nlm.nih.gov/pubmed/17346927,http://www.ncbi.nlm.nih.gov/pubmed/12788949,http://www.ncbi.nlm.nih.gov/pubmed/20188094,http://www.ncbi.nlm.nih.gov/pubmed/23818870,http://www.ncbi.nlm.nih.gov/pubmed/12118066,http://www.ncbi.nlm.nih.gov/pubmed/11846405,http://www.ncbi.nlm.nih.gov/pubmed/11275328,http://www.ncbi.nlm.nih.gov/pubmed/21510942,http://www.ncbi.nlm.nih.gov/pubmed/23114011,http://www.ncbi.nlm.nih.gov/pubmed/12925573,http://www.ncbi.nlm.nih.gov/pubmed/14690594,http://www.ncbi.nlm.nih.gov/pubmed/23857703,http://www.ncbi.nlm.nih.gov/pubmed/19325702,http://www.ncbi.nlm.nih.gov/pubmed/21175430,http://www.ncbi.nlm.nih.gov/pubmed/12018406,http://www.ncbi.nlm.nih.gov/pubmed/12045210,http://www.ncbi.nlm.nih.gov/pubmed/16828287,http://www.ncbi.nlm.nih.gov/pubmed/20736309,http://www.ncbi.nlm.nih.gov/pubmed/12554688,http://www.ncbi.nlm.nih.gov/pubmed/16410353,http://www.ncbi.nlm.nih.gov/pubmed/11733541,http://www.ncbi.nlm.nih.gov/pubmed/22647598,http://www.ncbi.nlm.nih.gov/pubmed/16289848,http://www.ncbi.nlm.nih.gov/pubmed/16262718,http://www.ncbi.nlm.nih.gov/pubmed/12829232,http://www.ncbi.nlm.nih.gov/pubmed/16914545,http://www.ncbi.nlm.nih.gov/pubmed/16787938 | Which is the enzymatic activity of the myotubularin family of proteins? | The myotubularin family of proteins are lipid inositol phosphatases |
http://www.ncbi.nlm.nih.gov/pubmed/15046306,http://www.ncbi.nlm.nih.gov/pubmed/12171605,http://www.ncbi.nlm.nih.gov/pubmed/15716010,http://www.ncbi.nlm.nih.gov/pubmed/9294192,http://www.ncbi.nlm.nih.gov/pubmed/18799480,http://www.ncbi.nlm.nih.gov/pubmed/9520433,http://www.ncbi.nlm.nih.gov/pubmed/10430918,http://www.ncbi.nlm.nih.gov/pubmed/9190805,http://www.ncbi.nlm.nih.gov/pubmed/7482779,http://www.ncbi.nlm.nih.gov/pubmed/10066522 | Can we detect DNA strand asymmetries using dinucleotide relative abundance "genomic signatures"? | The set of dinucleotide relative abundances can be regarded as a genomic signature because, despite diversity between species, it varies little between 50 kilobase or longer windows on a given genome. Thus, dinucleotide relative abundance profiles are species-type specific. These profiles are computed from the base step "odds ratios" that compare dinucleotide frequencies to those expected under the assumption of stochastic equilibrium (thorough shuffling). Dinucleotide relative abundance "genomic signatures" are strand-independent second-order DNA features. Thus, they cannot be used to detect DNA strand asymmetries. |
http://www.ncbi.nlm.nih.gov/pubmed/19808991,http://www.ncbi.nlm.nih.gov/pubmed/9040721,http://www.ncbi.nlm.nih.gov/pubmed/12710012,http://www.ncbi.nlm.nih.gov/pubmed/6128697,http://www.ncbi.nlm.nih.gov/pubmed/3400500,http://www.ncbi.nlm.nih.gov/pubmed/6502174,http://www.ncbi.nlm.nih.gov/pubmed/9549503,http://www.ncbi.nlm.nih.gov/pubmed/18555882,http://www.ncbi.nlm.nih.gov/pubmed/2904118,http://www.ncbi.nlm.nih.gov/pubmed/6889706,http://www.ncbi.nlm.nih.gov/pubmed/22515742 | What is the percentage of responders to tetrabenazine treatment for dystonia in children? | Tetrabenazine is used empirically in the treatment of dystonia in children with variable success. Observational studies report improvement of up to > 60% of the patients. |
http://www.ncbi.nlm.nih.gov/pubmed/23824326,http://www.ncbi.nlm.nih.gov/pubmed/19561118,http://www.ncbi.nlm.nih.gov/pubmed/23209445,http://www.ncbi.nlm.nih.gov/pubmed/22188810 | Is there any relationship between histone ubiquitylation and splicing? | Yes, in the case of histone H2B |
http://www.ncbi.nlm.nih.gov/pubmed/25404020,http://www.ncbi.nlm.nih.gov/pubmed/26288734,http://www.ncbi.nlm.nih.gov/pubmed/25327169,http://www.ncbi.nlm.nih.gov/pubmed/24729727,http://www.ncbi.nlm.nih.gov/pubmed/22670901 | Which disease can be treated with Delamanid? | Delamanid is used in patients with multidrug-resistant tuberculosis. |
http://www.ncbi.nlm.nih.gov/pubmed/21772967,http://www.ncbi.nlm.nih.gov/pubmed/22682265,http://www.ncbi.nlm.nih.gov/pubmed/23101451,http://www.ncbi.nlm.nih.gov/pubmed/22244016,http://www.ncbi.nlm.nih.gov/pubmed/22645702,http://www.ncbi.nlm.nih.gov/pubmed/22220280,http://www.ncbi.nlm.nih.gov/pubmed/22068990,http://www.ncbi.nlm.nih.gov/pubmed/21960571,http://www.ncbi.nlm.nih.gov/pubmed/23909253,http://www.ncbi.nlm.nih.gov/pubmed/24339571 | What was the aim of the COSS (Carotid Occlusion Surgery Study) clinical trial? | The Carotid Occlusion Surgery Study (COSS) was conducted to determine if superficial temporal artery-middle cerebral artery (STA-MCA) bypass, when added to the best medical therapy, would reduce subsequent ipsilateral stroke in patients with complete internal carotid artery (ICA) occlusion and an elevated oxygen extraction fraction (OEF) in the cerebral hemisphere distal to the occlusion. |
http://www.ncbi.nlm.nih.gov/pubmed/17652096,http://www.ncbi.nlm.nih.gov/pubmed/18381279,http://www.ncbi.nlm.nih.gov/pubmed/20879039,http://www.ncbi.nlm.nih.gov/pubmed/16457589,http://www.ncbi.nlm.nih.gov/pubmed/22647927,http://www.ncbi.nlm.nih.gov/pubmed/21898261,http://www.ncbi.nlm.nih.gov/pubmed/20848673,http://www.ncbi.nlm.nih.gov/pubmed/16457587,http://www.ncbi.nlm.nih.gov/pubmed/20486121,http://www.ncbi.nlm.nih.gov/pubmed/23466885,http://www.ncbi.nlm.nih.gov/pubmed/17569892,http://www.ncbi.nlm.nih.gov/pubmed/18302345,http://www.ncbi.nlm.nih.gov/pubmed/14976258,http://www.ncbi.nlm.nih.gov/pubmed/23034525,http://www.ncbi.nlm.nih.gov/pubmed/17967882,http://www.ncbi.nlm.nih.gov/pubmed/20707390,http://www.ncbi.nlm.nih.gov/pubmed/15025441,http://www.ncbi.nlm.nih.gov/pubmed/20202861,http://www.ncbi.nlm.nih.gov/pubmed/21249157,http://www.ncbi.nlm.nih.gov/pubmed/16457588 | What are the advantages of the top down mass spectrometric analysis of histones? | Top down mass spectrometry is a way to analyze intact proteins thus enabling: isoform characteriztion and analysis of post-translational modifications. |
http://www.ncbi.nlm.nih.gov/pubmed/26155517,http://www.ncbi.nlm.nih.gov/pubmed/26155468,http://www.ncbi.nlm.nih.gov/pubmed/26336554,http://www.ncbi.nlm.nih.gov/pubmed/26087838,http://www.ncbi.nlm.nih.gov/pubmed/25527777,http://www.ncbi.nlm.nih.gov/pubmed/25296948,http://www.ncbi.nlm.nih.gov/pubmed/25884612,http://www.ncbi.nlm.nih.gov/pubmed/26043594 | What is situs inversus? | Situs inversus totalis is a rare congenital anomaly with a complete mirror image of the thoracic and abdominal organs. |
http://www.ncbi.nlm.nih.gov/pubmed/10995744,http://www.ncbi.nlm.nih.gov/pubmed/23510938,http://www.ncbi.nlm.nih.gov/pubmed/24290762,http://www.ncbi.nlm.nih.gov/pubmed/21900893 | Can SUMO affect calcium homeostasis? | Yes, SUMO proteins can affect calcium homeostasis. |
http://www.ncbi.nlm.nih.gov/pubmed/12460666,http://www.ncbi.nlm.nih.gov/pubmed/22639778,http://www.ncbi.nlm.nih.gov/pubmed/16922811,http://www.ncbi.nlm.nih.gov/pubmed/6805141,http://www.ncbi.nlm.nih.gov/pubmed/21608438,http://www.ncbi.nlm.nih.gov/pubmed/10199151 | What is the indication of Daonil (Glibenclamide)? | Glibenclamide is an antidiabetic and antiglycemic, used in severe NIDDM, and increasingly viewed as a rational alternative to insulin therapy. |
http://www.ncbi.nlm.nih.gov/pubmed/10748089,http://www.ncbi.nlm.nih.gov/pubmed/15170512,http://www.ncbi.nlm.nih.gov/pubmed/7798312,http://www.ncbi.nlm.nih.gov/pubmed/9914159,http://www.ncbi.nlm.nih.gov/pubmed/1334264,http://www.ncbi.nlm.nih.gov/pubmed/9442098,http://www.ncbi.nlm.nih.gov/pubmed/8385108,http://www.ncbi.nlm.nih.gov/pubmed/9118249 | Which is the most typical peptide sequence responsible for retrieval of endoplasmic reticulum (ER) lumenal proteins from the Golgi apparatus? | The lumenal endoplasmic reticulum (ER) proteins carry a specific sorting signal which enables their retrieval from multiple post-ER compartments (up to the TGN along the exocytotic pathway), back to the ER. The most typical such signal is the carboxyl-terminal Lys-Asp-Glu-Leu (KDEL), which is bound by a KDEL receptor in the Golgi apparatus, as well as in the intermediate compartment. Thus KDEL functions as a retrieval signal of lumenal ER proteins from Golgi to ER. |
http://www.ncbi.nlm.nih.gov/pubmed/11473953,http://www.ncbi.nlm.nih.gov/pubmed/20517830,http://www.ncbi.nlm.nih.gov/pubmed/21631446,http://www.ncbi.nlm.nih.gov/pubmed/11836287,http://www.ncbi.nlm.nih.gov/pubmed/23412023,http://www.ncbi.nlm.nih.gov/pubmed/12364442,http://www.ncbi.nlm.nih.gov/pubmed/15802325,http://www.ncbi.nlm.nih.gov/pubmed/15117902,http://www.ncbi.nlm.nih.gov/pubmed/19342396 | What are the clinical trial outcomes of metformin use in polycystic ovary disease? | Metformin treatment vs placebo significantly but modestly improves ovulation frequency in women with abnormal ovarian function/oligomenorrhea and polycystic ovaries, the lower BMI women were more likely to become pregnant. While in naturally conceiving normal weight PCOS women pre-treatment with metformin tends to improve pregnancy rates, pre-treatment with metformin prior to conventional IVF/ICSI in women with PCOS does not improve stimulation or clinical outcome.
Metformin is an effective addition to Clomifene Citrate in term of reestablishment of ovulation and full-term pregnancies achievement.
Studies on the effect of metformin on serum Anti-Mullerian Hormone levels /AMH concentrations bring conflicting results, from Metformin having no effect on AMH to Metformin treatment resulting in significant decrease of AMH levels, antral follicle numbers and ovarian volume.
Metformin has been shown to cause significant weight loss (and leptin reduction) in PCOS. |
http://www.ncbi.nlm.nih.gov/pubmed/23728546,http://www.ncbi.nlm.nih.gov/pubmed/24140975,http://www.ncbi.nlm.nih.gov/pubmed/23606249,http://www.ncbi.nlm.nih.gov/pubmed/24106208,http://www.ncbi.nlm.nih.gov/pubmed/24012793,http://www.ncbi.nlm.nih.gov/pubmed/24136523,http://www.ncbi.nlm.nih.gov/pubmed/23576383,http://www.ncbi.nlm.nih.gov/pubmed/24168082,http://www.ncbi.nlm.nih.gov/pubmed/23710360,http://www.ncbi.nlm.nih.gov/pubmed/23703833,http://www.ncbi.nlm.nih.gov/pubmed/22324799,http://www.ncbi.nlm.nih.gov/pubmed/23792921,http://www.ncbi.nlm.nih.gov/pubmed/24133050,http://www.ncbi.nlm.nih.gov/pubmed/23580477,http://www.ncbi.nlm.nih.gov/pubmed/23454304,http://www.ncbi.nlm.nih.gov/pubmed/24144163,http://www.ncbi.nlm.nih.gov/pubmed/23943586,http://www.ncbi.nlm.nih.gov/pubmed/23775586,http://www.ncbi.nlm.nih.gov/pubmed/20218731,http://www.ncbi.nlm.nih.gov/pubmed/23819575,http://www.ncbi.nlm.nih.gov/pubmed/24116745 | List the main proteases used for sample digestion in proteomics. | Trypsin is the main protease used in proteomics followed by Asp-N, chymotrypsin, LysC, GluC and thermolysin. |
http://www.ncbi.nlm.nih.gov/pubmed/18707026,http://www.ncbi.nlm.nih.gov/pubmed/24554077,http://www.ncbi.nlm.nih.gov/pubmed/22427630,http://www.ncbi.nlm.nih.gov/pubmed/15687384,http://www.ncbi.nlm.nih.gov/pubmed/20110508,http://www.ncbi.nlm.nih.gov/pubmed/20702425,http://www.ncbi.nlm.nih.gov/pubmed/21559463,http://www.ncbi.nlm.nih.gov/pubmed/17572090,http://www.ncbi.nlm.nih.gov/pubmed/8807287,http://www.ncbi.nlm.nih.gov/pubmed/9535092,http://www.ncbi.nlm.nih.gov/pubmed/21145481,http://www.ncbi.nlm.nih.gov/pubmed/24118570,http://www.ncbi.nlm.nih.gov/pubmed/20696893,http://www.ncbi.nlm.nih.gov/pubmed/22749141,http://www.ncbi.nlm.nih.gov/pubmed/20638914,http://www.ncbi.nlm.nih.gov/pubmed/12086674,http://www.ncbi.nlm.nih.gov/pubmed/16469698,http://www.ncbi.nlm.nih.gov/pubmed/7869378,http://www.ncbi.nlm.nih.gov/pubmed/20178806,http://www.ncbi.nlm.nih.gov/pubmed/20436399,http://www.ncbi.nlm.nih.gov/pubmed/22960746 | Which proteins act as factors that promote transcription-coupled repair in bacteria? | Transcription coupled nucleotide excision repair (TC-NER or TCR) is a cellular process by which UV-induced damage and other road-blocks encountered in the transcribed strand are restored. Bacterial transcription-coupled repair is initiated when RNA polymerase stalled at a DNA lesion is removed by Mfd (Mutation frequency decline), an ATP-dependent DNA translocase. Mfd is the major transcription repair coupling factor in bacteria. Also, the transcription elongation factor NusA, in addition to its role in recruiting translesion synthesis (TLS) DNA polymerases to gaps encountered during transcription, promotes an alternative class of TCR involved in the identification and removal of a class of lesion, such as the N(2)-f-dG lesion. |
http://www.ncbi.nlm.nih.gov/pubmed/12947243,http://www.ncbi.nlm.nih.gov/pubmed/9133488,http://www.ncbi.nlm.nih.gov/pubmed/1474300,http://www.ncbi.nlm.nih.gov/pubmed/19321850,http://www.ncbi.nlm.nih.gov/pubmed/23929442,http://www.ncbi.nlm.nih.gov/pubmed/22549369,http://www.ncbi.nlm.nih.gov/pubmed/11769822,http://www.ncbi.nlm.nih.gov/pubmed/17450651,http://www.ncbi.nlm.nih.gov/pubmed/16998780,http://www.ncbi.nlm.nih.gov/pubmed/12063146,http://www.ncbi.nlm.nih.gov/pubmed/12490824 | What is the association between Generalized anxiety disorder and mortality risk? | Numerous studies have demonstrated that Generalized anxiety disorder is associated with increased mortality risk in different populations, including veterans and non demented elderly individuals. Anxiety disorders predict greater mortality, particularly when present with other psychiatric disorders. However, one study has found that generalized anxiety disorder was not associated with excess mortality in depressive elderly people. |
http://www.ncbi.nlm.nih.gov/pubmed/21824072,http://www.ncbi.nlm.nih.gov/pubmed/20021987,http://www.ncbi.nlm.nih.gov/pubmed/25199060,http://www.ncbi.nlm.nih.gov/pubmed/19929788,http://www.ncbi.nlm.nih.gov/pubmed/22092535,http://www.ncbi.nlm.nih.gov/pubmed/11496242,http://www.ncbi.nlm.nih.gov/pubmed/16184589,http://www.ncbi.nlm.nih.gov/pubmed/14699394,http://www.ncbi.nlm.nih.gov/pubmed/21346698,http://www.ncbi.nlm.nih.gov/pubmed/24424174,http://www.ncbi.nlm.nih.gov/pubmed/14523040,http://www.ncbi.nlm.nih.gov/pubmed/19264687,http://www.ncbi.nlm.nih.gov/pubmed/19264686,http://www.ncbi.nlm.nih.gov/pubmed/21958585,http://www.ncbi.nlm.nih.gov/pubmed/12704348,http://www.ncbi.nlm.nih.gov/pubmed/12870444,http://www.ncbi.nlm.nih.gov/pubmed/24685200,http://www.ncbi.nlm.nih.gov/pubmed/21348536,http://www.ncbi.nlm.nih.gov/pubmed/15175031,http://www.ncbi.nlm.nih.gov/pubmed/23257685,http://www.ncbi.nlm.nih.gov/pubmed/20110057,http://www.ncbi.nlm.nih.gov/pubmed/25199059,http://www.ncbi.nlm.nih.gov/pubmed/21790283,http://www.ncbi.nlm.nih.gov/pubmed/12406833,http://www.ncbi.nlm.nih.gov/pubmed/20810155,http://www.ncbi.nlm.nih.gov/pubmed/17872493,http://www.ncbi.nlm.nih.gov/pubmed/23742015,http://www.ncbi.nlm.nih.gov/pubmed/23844029,http://www.ncbi.nlm.nih.gov/pubmed/15813818,http://www.ncbi.nlm.nih.gov/pubmed/24322486,http://www.ncbi.nlm.nih.gov/pubmed/22998420,http://www.ncbi.nlm.nih.gov/pubmed/16462679,http://www.ncbi.nlm.nih.gov/pubmed/22541618,http://www.ncbi.nlm.nih.gov/pubmed/19828470,http://www.ncbi.nlm.nih.gov/pubmed/18298130,http://www.ncbi.nlm.nih.gov/pubmed/19243381,http://www.ncbi.nlm.nih.gov/pubmed/20513524,http://www.ncbi.nlm.nih.gov/pubmed/18344568,http://www.ncbi.nlm.nih.gov/pubmed/20565230,http://www.ncbi.nlm.nih.gov/pubmed/16931891,http://www.ncbi.nlm.nih.gov/pubmed/22901886,http://www.ncbi.nlm.nih.gov/pubmed/23362812,http://www.ncbi.nlm.nih.gov/pubmed/21443279,http://www.ncbi.nlm.nih.gov/pubmed/23544105 | Which molecule is targeted by a monoclonal antibody Mepolizumab? | Mepolizumab is a humanized monoclonal antibody that binds to and inactivates interleukin-5 that has been shown to reduce asthma exacerbations in patients with severe eosinophilic asthma. |
http://www.ncbi.nlm.nih.gov/pubmed/24696509,http://www.ncbi.nlm.nih.gov/pubmed/22266062,http://www.ncbi.nlm.nih.gov/pubmed/18990309,http://www.ncbi.nlm.nih.gov/pubmed/12073789,http://www.ncbi.nlm.nih.gov/pubmed/21396429,http://www.ncbi.nlm.nih.gov/pubmed/23159713,http://www.ncbi.nlm.nih.gov/pubmed/1396420,http://www.ncbi.nlm.nih.gov/pubmed/19049588,http://www.ncbi.nlm.nih.gov/pubmed/20722665,http://www.ncbi.nlm.nih.gov/pubmed/17105462,http://www.ncbi.nlm.nih.gov/pubmed/20472190,http://www.ncbi.nlm.nih.gov/pubmed/8214350,http://www.ncbi.nlm.nih.gov/pubmed/8243377,http://www.ncbi.nlm.nih.gov/pubmed/20301494,http://www.ncbi.nlm.nih.gov/pubmed/22780699,http://www.ncbi.nlm.nih.gov/pubmed/9184597,http://www.ncbi.nlm.nih.gov/pubmed/10768159,http://www.ncbi.nlm.nih.gov/pubmed/8891396,http://www.ncbi.nlm.nih.gov/pubmed/22322415,http://www.ncbi.nlm.nih.gov/pubmed/21351810,http://www.ncbi.nlm.nih.gov/pubmed/8753132,http://www.ncbi.nlm.nih.gov/pubmed/23941843,http://www.ncbi.nlm.nih.gov/pubmed/2115971 | Which is the major symptom of the Doose syndrome? | Myoclonic astatic epilepsy is the major symptom of the Doose syndrome, which is a difficult to treat idiopathic generalized epilepsy of early childhood. |
http://www.ncbi.nlm.nih.gov/pubmed/17035524,http://www.ncbi.nlm.nih.gov/pubmed/23990368,http://www.ncbi.nlm.nih.gov/pubmed/20301462,http://www.ncbi.nlm.nih.gov/pubmed/16982418,http://www.ncbi.nlm.nih.gov/pubmed/16014653,http://www.ncbi.nlm.nih.gov/pubmed/20301420,http://www.ncbi.nlm.nih.gov/pubmed/22462675,http://www.ncbi.nlm.nih.gov/pubmed/17663003,http://www.ncbi.nlm.nih.gov/pubmed/22144914,http://www.ncbi.nlm.nih.gov/pubmed/16769947,http://www.ncbi.nlm.nih.gov/pubmed/19412816 | Have mutations in the GARS gene been identified to cause Charcot-Marie-Tooth Disease Type 2D (CMT2D)? | Charcot-Marie-Tooth disease type 2D (CMT2D) is caused by missense mutations in the glycyl-tRNA synthetase gene (GARS). |
http://www.ncbi.nlm.nih.gov/pubmed/7529539,http://www.ncbi.nlm.nih.gov/pubmed/2683920,http://www.ncbi.nlm.nih.gov/pubmed/1705835,http://www.ncbi.nlm.nih.gov/pubmed/1689595,http://www.ncbi.nlm.nih.gov/pubmed/10779444,http://www.ncbi.nlm.nih.gov/pubmed/21052952,http://www.ncbi.nlm.nih.gov/pubmed/16822461 | Which treatment leads to an increase in neutrophil counts in severe congenital neutropenia? | In phase I/II/III studies in patients with severe congenital and cyclic neutropenia, treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) resulted in a rise in the absolute neutrophil counts (ANC) and a reduction in infections In patients with severe congenital and cyclic neutropenia, treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) resulted in a rise in the absolute neutrophil counts (ANC) and a reduction in infections. |
http://www.ncbi.nlm.nih.gov/pubmed/10482963,http://www.ncbi.nlm.nih.gov/pubmed/15511625,http://www.ncbi.nlm.nih.gov/pubmed/20981542,http://www.ncbi.nlm.nih.gov/pubmed/19490272,http://www.ncbi.nlm.nih.gov/pubmed/9511785,http://www.ncbi.nlm.nih.gov/pubmed/15950200,http://www.ncbi.nlm.nih.gov/pubmed/12388934,http://www.ncbi.nlm.nih.gov/pubmed/10953551,http://www.ncbi.nlm.nih.gov/pubmed/17560885,http://www.ncbi.nlm.nih.gov/pubmed/10973849,http://www.ncbi.nlm.nih.gov/pubmed/16931984,http://www.ncbi.nlm.nih.gov/pubmed/16981927,http://www.ncbi.nlm.nih.gov/pubmed/9848024,http://www.ncbi.nlm.nih.gov/pubmed/9641694,http://www.ncbi.nlm.nih.gov/pubmed/10613047,http://www.ncbi.nlm.nih.gov/pubmed/20301308,http://www.ncbi.nlm.nih.gov/pubmed/10868746,http://www.ncbi.nlm.nih.gov/pubmed/20850564,http://www.ncbi.nlm.nih.gov/pubmed/19540844,http://www.ncbi.nlm.nih.gov/pubmed/9791861,http://www.ncbi.nlm.nih.gov/pubmed/18752142,http://www.ncbi.nlm.nih.gov/pubmed/16831322,http://www.ncbi.nlm.nih.gov/pubmed/14756674,http://www.ncbi.nlm.nih.gov/pubmed/23000022,http://www.ncbi.nlm.nih.gov/pubmed/12442276,http://www.ncbi.nlm.nih.gov/pubmed/10898405,http://www.ncbi.nlm.nih.gov/pubmed/10220144,http://www.ncbi.nlm.nih.gov/pubmed/10560244,http://www.ncbi.nlm.nih.gov/pubmed/15306731,http://www.ncbi.nlm.nih.gov/pubmed/22461049,http://www.ncbi.nlm.nih.gov/pubmed/11216980 | Which genes are affected in ROMANO-WARD syndrome? | The genes involved in ROMANO-WARD syndrome are KCNQ1, KCNE1, KCNE2, KCNH2, SCN5A, CAV3, SCN4B, AKAP9, SNTA1, KCNJ5 and Ankyrin-B. |
http://www.ncbi.nlm.nih.gov/pubmed/1920508,http://www.ncbi.nlm.nih.gov/pubmed/20415670,http://www.ncbi.nlm.nih.gov/pubmed/8260178,http://www.ncbi.nlm.nih.gov/pubmed/19538377,http://www.ncbi.nlm.nih.gov/pubmed/19450404,http://www.ncbi.nlm.nih.gov/pubmed/475965,http://www.ncbi.nlm.nih.gov/pubmed/15540891,http://www.ncbi.nlm.nih.gov/pubmed/12883369,http://www.ncbi.nlm.nih.gov/pubmed/1135705,http://www.ncbi.nlm.nih.gov/pubmed/876685,http://www.ncbi.nlm.nih.gov/pubmed/8000657,http://www.ncbi.nlm.nih.gov/pubmed/8402099,http://www.ncbi.nlm.nih.gov/pubmed/1138394,http://www.ncbi.nlm.nih.gov/pubmed/5776549,http://www.ncbi.nlm.nih.gov/pubmed/1156726,http://www.ncbi.nlm.nih.gov/pubmed/18227705,http://www.ncbi.nlm.nih.gov/pubmed/10461463,http://www.ncbi.nlm.nih.gov/pubmed/97949,http://www.ncbi.nlm.nih.gov/pubmed/11205232 | Does melanoma occur in people of African origin ? | Yes. Africans with dark skin have a reduced risk of getting all types of skin cancer as compared with Caucasians. The incidence of malignant melanoma in Johannesburg Black was 1,2 per 100 000 and accounted for 2% of all cancers. The largest number of cases occurred in the 50- 70-year age group and there was a female preponderance. As in previous studies, the sites predominantly affected were the foot and the hand, mainly on the plantar and palmar surfaces. |
http://www.ncbi.nlm.nih.gov/pubmed/23272906,http://www.ncbi.nlm.nih.gov/pubmed/23211629,http://www.ncbi.nlm.nih.gov/pubmed/22242130,http://www.ncbi.nlm.nih.gov/pubmed/21966552,http://www.ncbi.nlm.nih.gov/pubmed/24060150,http://www.ncbi.nlm.nih.gov/pubmed/22530672,http://www.ncbi.nlm.nih.gov/pubmed/23680031,http://www.ncbi.nlm.nih.gov/pubmed/21179458,http://www.ncbi.nlm.nih.gov/pubmed/22269797,http://www.ncbi.nlm.nih.gov/pubmed/22029423,http://www.ncbi.nlm.nih.gov/pubmed/21168265,http://www.ncbi.nlm.nih.gov/pubmed/19108833,http://www.ncbi.nlm.nih.gov/pubmed/19827268,http://www.ncbi.nlm.nih.gov/pubmed/19471118,http://www.ncbi.nlm.nih.gov/pubmed/20851890,http://www.ncbi.nlm.nih.gov/pubmed/23248098,http://www.ncbi.nlm.nih.gov/pubmed/25448084,http://www.ncbi.nlm.nih.gov/pubmed/20169165 | What is the effect of resveratrol on mTOR activity? | Resveratrol (RSV) inhibits leucine-stimulated mTORC1 activation by promoting mTOR/DEPTOR.Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human cells. It has been found that resveratrol targets multiple components of the phosphatidylinositol 3- kinase(PI3K)/Akt and mTOR signaling pathways, including PI3K, Akt, PTEN, and DEPTOR, suggesting that this natural compound and its derivatives may offer a promising new cancer treatment. |
http://www.ncbi.nlm.nih.gov/pubmed/22771625,http://www.ncbi.nlm.nih.gov/pubmed/15814030,http://www.ncbi.nlm.nih.gov/pubmed/23071435,http://www.ncbi.nlm.nih.gov/pubmed/22818742,http://www.ncbi.nlm.nih.gov/pubmed/17959777 | Are people with blood group O protected against severe Malaria? | It appears that individuals who are of blood-group O are relatively resistant to the severe disease caused by P. falciparum infection. |
http://www.ncbi.nlm.nih.gov/pubmed/21117539,http://www.ncbi.nlm.nih.gov/pubmed/24763473,http://www.ncbi.nlm.nih.gov/pubmed/25176050,http://www.ncbi.nlm.nih.gov/pubmed/22347790,http://www.ncbi.nlm.nih.gov/pubmed/24893359 | Which eye condition is managed by the athens protocol? | The athens protocol (transepithelial topography-guided PRK therapeutic remodeling, combined with same-day, collagen cross-linking) was developed for the management of cornea blindness due to severe corneal scarring. |
http://www.ncbi.nlm.nih.gov/pubmed/16155579,http://www.ncbi.nlm.nih.gov/pubmed/23122726,http://www.ncbi.nlm.nih.gov/pubmed/22344560,http://www.ncbi.nlm.nih.gov/pubmed/22043210,http://www.ncbi.nlm.nih.gov/pubmed/21572014 | What is the role of AMPK kinase in myocardial remodeling after myocardial infarction | AMP-activated protein kinase (AMPK) is a key sensor of cellular energy. The activation of AMPK by metformin prevents cardiac remodeling after myocardial infarction (MI).
Adiponectin protects the heart from ischemia-reperfusion injury through an AMPK-dependent mechanism.
AMPK activation by metformin and the subsequent suppression of TLRs activity could be considered as a target in protecting the infarcted heart. |
http://www.ncbi.nlm.nih.gov/pubmed/24101429,http://www.ncbi.nlm.nih.gov/pubmed/21784350,http://www.ncbi.nlm.nih.gov/pubmed/21868184,http://www.ncbi.nlm.nih.gov/pubmed/24353405,http://www.ncbi.nlm.nih.gov/pubmed/24063020,http://www.ncbi.nlm.nih.gov/pubmed/22482074,http://www.ncbi.nlm.nih.gov/pubmed/21504387,http://www.ncbi.nlm.nih.gov/pubmed/22848160,http://www.ncbi.nlm.nih.gov/pubmed/24259408,http://www.ncbi.nlm.nih.gov/pubmed/22506132,http://www.ncbi.nlm.nih.gov/pubmed/23582316,http://www.ncbi.nlm.nih.gov/pubmed/23847530,http://www.ncbi.nlm.nih.gov/pubmed/22110351,http://www.ncbi.nlm.nih.gov/pubmed/21694458,http://www.ncbi.nlm.nih.gov/pubmed/22292124,http://www.ncbi.nlm.nih.gov/pubmed/23254906,http://www.ncbi.nlm.nih.gov/pubmed/23574434,http://www.ncbi.nlm.nih.gov/pubmed/22288451,http://www.ncbi.nlm.nih.gov/pubmed/21897718,http://www.ncbi.nlm.nih.gov/pubmed/22134132,http://www.ncbi.nlm.nih.gov/pubmed/22672770,http://www.ncbi.nlm.nih.gov/pubmed/23416764,http://www.ncbi.nlm.nih.gov/pubmed/23735288,http://www.ncbi.nlm.nih.gov/pubmed/22339463,http://www.ncbi.nlm.nih.gov/pubmed/23568994,http://www.ncbi.nlm.nih.gov/pubmed/23663286,http://www.ncbi.nlm.nih.gov/pubmed/20375655,http://www.ncbi.nlm.nih.gov/pubmed/21614635,http://www.ncbi.nlm.nih.gov/pubmed/24119446,http://www.ncbi.nlm.nih.gov/pubmed/24399967 | What is the mechanism of action of solanezumab? | Solanezumab is a monoclonal anti-amyloid beta peptide (Aβ) antibody. It has been tested for treatment of Alzheimer's disease patients.Solanezumab, a humanized anti-Aβ monoclonal antibody directed against the midregion of the Aβ peptide, was shown to neutralize soluble Aβ species. |
http://www.ncbi.nlm.nih.gov/pubmed/22696272 | What are the major clinical Villefranche criteria for classic Ehlers-Danlos syndrome? | The major clinical Villefranche criteria for classic Ehlers-Danlos syndrome are skin hyperextensibility, dystrophic scarring, and joint hypermobility. |
http://www.ncbi.nlm.nih.gov/pubmed/22401313,http://www.ncbi.nlm.nih.gov/pubmed/22147611,http://www.ncbi.nlm.nih.gov/pubmed/18363625,http://www.ncbi.nlm.nih.gov/pubmed/7561230,http://www.ncbi.nlm.nih.gov/pubmed/15265351,http://www.ncbi.nlm.nih.gov/pubmed/22735246,http://www.ncbi.nlm.nih.gov/pubmed/18820538,http://www.ncbi.nlm.nih.gov/pubmed/12712053,http://www.ncbi.nlm.nih.gov/pubmed/21332246,http://www.ncbi.nlm.nih.gov/pubmed/11902308 | What is the treatment of neuropathic pain in children? | It is unclear if any treatment is registered for pediatric use. The reported treatments are:
Oxcarbazepine
Opioids alone, in rotations or with Analgesics (e.g. Ketamine and Lidocaine infusion)
Opioids and Benzodiazepines
Pregabalin - is one of the first drugs registered for the treatment of neuropathic pain. It is unclear if Pregabalin is registered for the treatment of neuropathic pain in children specifically but it is being used in practice.
Tricyclic Antidepressants
Lidocaine 5% patches for chronic localized neuropathic pain |
http://www.ncbi.nlm.nih.gov/pubmed/16901476,http://www.ncbi.nlm.nih.gov/pubmed/6626051,http://www.ncbi.nlm.nih.gov/pubmed/4058248,http://www.ncbi.nlm.nih.gov/pubmed/1031954,http://www.ncbi.nlm.nih.gov/pubmed/2720439,http://www.ncbi.nlm.nih.gov/pubmed/6823106,http://www.ncbi.nlm.nih.gov/pubmed/24289081,http://www.ncbi.nlm.nih.gov/pubmed/23284963,http://www.ncbi.nlm.nih.gov/pubmed/3117031 | Which phenomenon is known as the "calcium paradox" in the isolated perfused heart? | When hearts are reperfused with Ca++ after a short period of Ca++-free perfusion, irreversible loss of electrical and mechanical activity is observed. This phenomenon, first described by Zimmerman and Hulsmann, was termed the "calcium paradox". This phenomenon is concomitant with a rapid consumption of myocardial high-energy phosphate stores. The Ca(2+) paradox represents a good model to study Ca(2+) overload injury in ischemic heart diseases. The Ca(2+) paradox can be elicited by perfusing isolated hearts with Ca(2+)-free media for 3 min or 5 min followed by 30 min of Ca(2+) repletion. A possible mechanism for the 'calcium paradox' is that exposure to a calcium-free medium removes extracellular calcium rendering the sarcolemma more permeable to calcium. On calcium repletion, cell injury is triggered by calcium influx. Cardiac dysfunction due to Ca2+ -paradox may be associated with apoptosis.Isolated perfusion of the heart with a Ca2+-free perfusate followed by a Ca2+-containing perfusate causes dramatic alterations in the physiology and biochemistry of the tissue, a phenomenon known as the calcium paradox. A similar paradoxical effect of Ca2+ has also been reported to occur in the kidney When isolated rat hearts are perfused with Ca2+-containing medium, after a brief Ca2+-free period, irreversible cell damage occurs (calcium paradox). This phenomenon is concomitant with a rapid consumption of myocardial high-energy phosphate stores, prior to the appearance of these compounds in the effluent perfusion medium. Isolated perfusion of the heart with a Ca2+-free perfusate followed by a Ca2+-containing perfusate causes dramatic alterations in the physiology and biochemistry of the tissue, a phenomenon known as the calcium paradox. A similar paradoxical effect of Ca2+ has also been reported to occur in the kidney When isolated rat hearts are perfused with Ca2+-containing medium, after a brief Ca2+-free period, irreversible cell damage occurs (calcium paradox). This phenomenon is concomitant with a rapid consumption of myocardial high-energy phosphate stores, prior to the appearance of these compounds in the effluent perfusion medium. When hearts were reperfused with Ca++ after a short period of Ca++-free perfusion, irreversible loss of electrical and mechanical activity was observed. This phenomenon, first described by Zimmerman and Hulsmann, was termed the calcium paradox . Chizzonite and Zak recently reported that rat hearts exhibited an age-dependent response in a calcium paradox model. "Calcium paradox" as a term describes the deleterious effects conferred to a heart perfused with a calcium-free solution followed by repletion, including loss of mechanical activity and sarcomere disruption.Isolated perfusion of the heart with a Ca2+-free perfusate followed by a Ca2+-containing perfusate causes dramatic alterations in the physiology and biochemistry of the tissue, a phenomenon known as the calcium paradox. A similar paradoxical effect of Ca2+ has also been reported to occur in the kidney |
http://www.ncbi.nlm.nih.gov/pubmed/22365326,http://www.ncbi.nlm.nih.gov/pubmed/19710254,http://www.ncbi.nlm.nih.gov/pubmed/23355615,http://www.ncbi.nlm.nih.gov/pubmed/22757685,http://www.ncbi.nlm.nih.gov/pubmed/17287213,http://www.ncbi.nlm.nih.gov/pubmed/23950717 | Is there a crystal structure of the full-length of the flaviviridae NS5(Methyltransferase - RNA depended RNA Polymerase) ? | Yes, there is the crystal Structure of the full-length Japanese encephalitis virus (Flaviviridae) NS5 - PDB:4K6M |
http://www.ncbi.nlm.nih.gov/pubmed/10358092 | How do Hsp70 and Hsp110 affect mRNA stability? | Hsp70 and Hsp110 act as RNA-binding entities in vivo to guide the appropriate folding of RNA substrates for subsequent regulatory processes such as mRNA degradation and/or translation. |
http://www.ncbi.nlm.nih.gov/pubmed/23741179,http://www.ncbi.nlm.nih.gov/pubmed/17076904,http://www.ncbi.nlm.nih.gov/pubmed/20624672,http://www.ncbi.nlm.nih.gov/pubmed/2173390,http://www.ncbi.nlm.nih.gov/pubmed/22034645,http://www.ncbi.nlm.nih.gov/pubmed/23953031,http://www.ncbi.nlm.nih.gov/pubmed/207959,http://www.ncbi.nlm.nih.gov/pubmed/6622440,http://www.ncbi.nlm.nih.gov/pubmed/23639938,http://www.ncbi.nlm.nih.gov/pubmed/11493127,http://www.ncbi.nlm.nih.gov/pubmed/16580586,http://www.ncbi.nlm.nih.gov/pubmed/22835136,http://www.ncbi.nlm.nih.gov/pubmed/21676220,http://www.ncbi.nlm.nih.gov/pubmed/15853117,http://www.ncbi.nlm.nih.gov/pubmed/23885043,http://www.ncbi.nlm.nih.gov/pubmed/23524862,http://www.ncbi.nlm.nih.gov/pubmed/23530637,http://www.ncbi.nlm.nih.gov/pubmed/1511475,http://www.ncbi.nlm.nih.gov/pubmed/18796495,http://www.ncbi.nlm.nih.gov/pubmed/4072955,http://www.ncbi.nlm.nih.gov/pubmed/7870637,http://www.ncbi.nlm.nih.gov/pubmed/22914994,http://www.ncbi.nlm.nih.gov/pubmed/23933622,http://www.ncbi.nlm.nih.gov/pubmed/3819235,http://www.ncbi.nlm.nih.gov/pubmed/216895,http://www.ncbi.nlm.nih.gov/pubmed/22717188,http://www.ncbi.nlm.nih.gov/pubmed/1852180,http://www.ncbi.nlm.nih.gov/pubmed/422845,http://www.ncbi.nlm.nih.gov/pubmed/23398686,http://www.ncbi.nlm.nih.gov/pubmed/15539255,http://www.ncbi.nlm.nih.gov/pubmed/3886611 | What is Prudent Diet? | The Prudent dietary pattern is characterised by high intakes of vegetables, fruits, whole grain products and low intakes of refined grain products, legumes, fish, poultry. Generally recommendations are to use saturated/trans fat intake less than 10% of total calories and cholesterol less than 300 mg/day and/or fiber intake ≥ 25 g/day in women and ≥ 35 grams per day in men. |
http://www.ncbi.nlm.nih.gov/pubmed/23875666,http://www.ncbi.nlm.nih.gov/pubmed/23301705,http://www.ncbi.nlm.nih.gov/pubmed/23625539,http://www.ncbi.nlm.nih.gov/pubmed/23729362 | What is the role of necroptosis in cancer therapy? | Necroptosis, a novel form of programmed cell death (PCD), is caspase independent but RIPK and RIPK3 dependent. The apoptotic, autophagic and necroptotic pathways of PCD were shown to be interconnected, with molecules such as FLIP acting as a bridge between them. Therefore, simultaneous activation of the three PCD pathways would make cancer therapy more effective, whereas induction of necroptosis could be an alternative, in cases where apoptosis-inducing cancer chemotherapy is not effective. For example, inhibition of GSK3B was found to bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to 5-FU treatment. |
http://www.ncbi.nlm.nih.gov/pubmed/10490914,http://www.ncbi.nlm.nih.gov/pubmed/9252010,http://www.ncbi.nlm.nih.gov/pubmed/12784104,http://www.ncbi.nlm.nih.gov/pubmed/16140280,http://www.ncbi.nlm.nih.gov/pubmed/23090625,http://www.ncbi.nlm.nih.gov/pubmed/15989562,http://www.ncbi.nlm.nih.gov/pubmed/18923402,http://www.ncbi.nlm.nih.gov/pubmed/18418363,http://www.ncbi.nlm.nih.gov/pubmed/18538356,http://www.ncbi.nlm.nih.gov/pubmed/11454918,http://www.ncbi.nlm.nih.gov/pubmed/10884561,http://www.ncbi.nlm.nih.gov/pubmed/11524036,http://www.ncbi.nlm.nih.gov/pubmed/9400006 | Can venlafaxine block NET and SERT? | Yes, venlafaxine inhibits both the NET and SERT. |
http://www.ncbi.nlm.nih.gov/pubmed/21340496,http://www.ncbi.nlm.nih.gov/pubmed/22853635,http://www.ncbi.nlm.nih.gov/pubmed/19158113,http://www.ncbi.nlm.nih.gov/pubmed/20889597,http://www.ncbi.nlm.nih.gov/pubmed/18759162,http://www.ncbi.nlm.nih.gov/pubmed/16418123,http://www.ncbi.nlm.nih.gov/pubmed/17965425,http://www.ncbi.nlm.nih.gov/pubmed/15083883,http://www.ncbi.nlm.nih.gov/pubmed/1563036,http://www.ncbi.nlm.nih.gov/pubmed/12723987,http://www.ncbi.nlm.nih.gov/pubmed/20810033,http://www.ncbi.nlm.nih.gov/pubmed/23217568 | Is Rheumatoid Arthritis more common in men or women? | Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome. |
http://www.ncbi.nlm.nih.gov/pubmed/21113021,http://www.ncbi.nlm.nih.gov/pubmed/17135191,http://www.ncbi.nlm.nih.gov/pubmed/22659238,http://www.ncbi.nlm.nih.gov/pubmed/24234438 | What is FINDbase? | Frequency of INherited Disorders database (FINDbase) (http://www.findbase.org) is a relational database, derived from the ETHNOS software, recording frequencies of causative mutations leading to inherited disorders worldwide. Database records include the population and ethnic group, the disorder name and the related gene, accompanied by links to any corresponding locus-specific mutation database, to the respective Online Mendelian Inheritance in Man entries and the mutation together with its frequency in that population. The initial information is derived from the published literature, locus-specific databases and genetic disease consortia. FINDbase offers a user-friendly query interface, providing instant access to the list and frequencies of the different mutations. Query outputs can be either in a table or graphical format, accompanied by reference(s) on the data source. Registered users from three different groups, namely administrator, national coordinator and curator, are responsible for database curation and/or data entry/correction online via a password-protected interface. Database access is free of charge and there are no registration requirements for data querying. FINDbase provides a simple, web-based system for population-based mutation data collection and retrieval and can serve not only as a valuable online tool for molecular genetic testing of inherited disorders but also as a non-profit model for sustainable database funding, in the form of a 'database-journal'.Frequency of INherited Disorders database (FINDbase) (http://www.findbase.org) is a relational database, derived from the ETHNOS software, recording frequencies of causative mutations leading to inherited disorders worldwide. Database records include the population and ethnic group, the disorder name and the related gene, accompanied by links to any corresponding locus-specific mutation database, to the respective Online Mendelian Inheritance in Man entries and the mutation together with its frequency in that population. FINDbase provides a simple, web-based system for population-based mutation data collection and retrieval and can serve not only as a valuable online tool for molecular genetic testing of inherited disorders but also as a non-profit model for sustainable database funding, in the form of a 'database-journal'. |
http://www.ncbi.nlm.nih.gov/pubmed/9279523,http://www.ncbi.nlm.nih.gov/pubmed/20943242,http://www.ncbi.nlm.nih.gov/pubmed/23042832,http://www.ncbi.nlm.nih.gov/pubmed/24620429,http://www.ncbi.nlm.nih.gov/pubmed/24379094,http://www.ncbi.nlm.nih.gov/pubmed/24973622,http://www.ncbi.nlm.nih.gov/pubmed/23935638,http://www.ncbi.nlm.nih.gov/pubmed/23090806,http://www.ncbi.nlm.nih.gov/pubmed/25515801,http://www.ncbi.nlm.nih.gov/pubmed/14644703,http://www.ncbi.nlm.nih.gov/pubmed/22703872,http://www.ncbi.nlm.nih.gov/pubmed/24117525,http://www.ncbi.nlm.nih.gov/pubmed/25276464,http://www.ncbi.nlm.nih.gov/pubmed/7695937,http://www.ncbi.nlm.nih.gov/pubmed/23278769,http://www.ncbi.nlm.nih.gov/pubmed/23715222,http://www.ncbi.nlm.nih.gov/pubmed/16254404,http://www.ncbi.nlm.nih.gov/pubmed/25050351,http://www.ncbi.nlm.nih.gov/pubmed/21217196,http://www.ncbi.nlm.nih.gov/pubmed/24701066,http://www.ncbi.nlm.nih.gov/pubmed/11304071,http://www.ncbi.nlm.nih.gov/pubmed/2361826 | Can vitamin B1 deficiency cause encephalopathy? | Wernicke's encephalopathy (WE) is a severe neurological syndrome caused by thiamine (vitamin B1) deficiency and clinically characterized by the sudden onset of mental status changes, ocular abnormalities, and ataxia. It is commonly associated with heavy alcohol consumption. Other clinical associations are with hyperemesis gravidarum (HG), starvation, and prolonged intravenous feeding.Wernicke's encephalopathy (WE) is a severe neurological syndrome caused by thiamine (vitamin B1) deficiency and clinically characterized by the sudden onset of mental status changes, ocular abnormalities, and ataxia |
http://www.ncbi.nlm.nih.gov/pubmed/18534925,http://www.ncbi.nlm.nih.gov/pubmed/22138506,http://www.ncbi.nlm.nih.gov/pubmed/22302819,http://www.ncbi.nlm.nih.gov/pubmed/11180222 | Which methyl-CpG-binding protein when mutant becomes the hallmark for Rett syndrome? | Rett syndrome (RTT) was shown to be caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene, with molecular studies identifying MECP2 mutations in up to 80% of classic RTT patients. MECP2 protein was found to assist in the transcriptional silencing process via DNA methylation. We therefore hypothesize that disruption of this gene alters the normal developmental expression of various other genes, some of which must account for the peculiar neurologic phenotype of RTT. |
http://www.ncbi.nlm.nih.gov/pubmed/22773406,http://www.ncbi.nlm.nih.gov/pubmed/22981780,http://www.ncbi.nlm.nih.gov/pubmed/20603647,http://www.ncbi.nlm.nih.gov/pubmed/21372004,http://www.ncbi.nlm.nih.gov/pubmed/23448446,http://www.ncbi.nlm.nih.gov/pubmed/22035349,http://www.ncbi.nlm.nih.gov/pubmed/23261320,http://www.ncbi.nlm.nih.gov/pubmed/19488075,http://www.ncbi.nlm.nih.gov/pubmed/23640490,http://www.ncbi.nlm.nih.gov/pubmed/21764886,http://www.ncbi.nlm.nih.gov/pubmed/20881938,http://www.ncbi.nlm.nih.gov/pubmed/22234702,http://www.ncbi.nlm.nih.gov/pubmed/24183004,http://www.ncbi.nlm.nih.gov/pubmed/22669047,http://www.ncbi.nlm.nih.gov/pubmed/22621747 | Are epigenetic modifications implicated in cardiovascular development and disease? | Genetic and epigenetic factors are of great importance in cardiovascular biology and disease. Aberrant epigenetic mechanisms may lead to pathological consequences such as cardiovascular disease (CAD).Recent studies have greatly expanded our understanding of the regulation of cardiovascular development at the chromatin level, including the remodeling of chromatin and the modification of histones. Thus, understanding chromatin-level regulation will allow for a better appreciation of gene regulation as a whole and may set a fundamental basis for cardiovascular disease. |
http://www.ncbi.nlm.nih.gov/pubmed/19293265,http://www.ncbi.nlm.nih.gov/pubmed/17986277,http://www.ncbi.nlm.nih.gov/pubmed/23396445,http://www.ncbi.nlm.nih.gov/pubmed/16127464 | Which deiodinases are present in skeletal muscle? | Type 2 and Type 3 deiodinases are expressed in skeletal muscle and their expression is modulated by disease state and fasting. |
http://www.ncbi.nlm.nih.gov/pubmed/23208322,http://www.ncbi.nlm.nih.gov/pubmed/22321278,http://www.ncbi.nlm.nih.gov/pubmed/22023024,http://www.ncbi.nlm.nih.gov/pubmed/21651319,http://www.ncbi.nlm.nih.gov/pubmed/17496169,http://www.ncbi.nlm.nih.gov/pubmed/19348697,http://www.ncbi.nlm.nih.gov/pubmed/18464049,http://www.ncbi.nlm.nih.gov/pubmed/19794411,http://www.ncbi.nlm.nih.gov/pubmed/21590310,http://www.ncbi.nlm.nih.gov/pubmed/22122181,http://www.ncbi.nlm.nih.gov/pubmed/21713343,http://www.ncbi.nlm.nih.gov/pubmed/18034618,http://www.ncbi.nlm.nih.gov/pubmed/19538716,http://www.ncbi.nlm.nih.gov/pubmed/20615525,http://www.ncbi.nlm.nih.gov/pubmed/19069171,http://www.ncbi.nlm.nih.gov/pubmed/20210733,http://www.ncbi.nlm.nih.gov/pubmed/19752777,http://www.ncbi.nlm.nih.gov/pubmed/19135231,http://www.ncbi.nlm.nih.gov/pubmed/16611750,http://www.ncbi.nlm.nih.gov/pubmed/20854800,http://www.ncbi.nlm.nih.gov/pubmed/11213860,http://www.ncbi.nlm.nih.gov/pubmed/23342320,http://www.ncbi.nlm.nih.gov/pubmed/18752379,http://www.ncbi.nlm.nih.gov/pubmed/22952875 | Which genes are involved in patient response to warfarin? | The following genes have been associated with patient response to warfarin: CYP2C9, VKORC1, ORM1, CYP4F2, EPHX1, CYP2C18, CYP2C19, CYP3A5, protein S, clotting factor V, PROC, GGCX. |
http://www.ncbi.nlm.nih.gov/pubmed/7585697,http://www.ncbi.nlm.nih.gov/pubmed/1723310,http://www.ncbi.nlm.nih.gov/pubmed/18055286,http://www.ncbi.nlm.nih.gov/pubmed/2775757,http://www.ncbi.nlm.nih.gov/pubmed/10486275,http://www.ncbi.nlm.nih.gov/pubmed/8574597,http://www.ncbi.nlm.nih.gov/pubmed/10673358,http://www.ncbi.nlm.nih.gov/pubmed/10441122,http://www.ncbi.nlm.nih.gov/pubmed/4074709 | Which is the molecular weight of the protein angiogenin? | The molecular weight of angiogenin is 14,120 Da. The bovine angiogenin is 14,595 Da |
http://www.ncbi.nlm.nih.gov/pubmed/24040872,http://www.ncbi.nlm.nih.gov/pubmed/22632452,http://www.ncbi.nlm.nih.gov/pubmed/25488697,http://www.ncbi.nlm.nih.gov/pubmed/22433611,http://www.ncbi.nlm.nih.gov/pubmed/24741548,http://www.ncbi.nlm.nih.gov/pubmed/24455799,http://www.ncbi.nlm.nih.gov/pubmed/25414933,http://www.ncbi.nlm.nih.gov/pubmed/24585202,http://www.ncbi.nlm.nih.gov/pubmed/25255411,http://www.ncbi.nlm.nih.gov/pubmed/24059302,http://www.ncbi.nlm.nih.gov/pubmed/25598831,http://www.ncbi.nlm.nih.gov/pubmed/25688893,http://www.ncbi.nlm.nih.gov/pubmed/24998153,http://www.ncbi.nlm.nih.gov/pubmed/23194084,http://www.ncbi.nlm.nih.gov/pubmed/25712444,http://www.ncbi.nlm.nih.gov/pubmed/24633706,http://www.ncbi.nlm.nih.gov/pubmed/22583331,http://www.ncbi.nlm.nih.gov/pubmed/19243283,http://www.ncbi.nlm.nih.gov/pubmed/24025022,http://www.ncbi.nlm.nih.gov/pubmed/24950857,http://www.ncbi.nlm.nih.gov/pubmed/24705156,http://www.ncbi.nlm.nih.gov/pubmed/25059406,http://www.ncbi.nlm.nih.gov/pubmed/23729000,http://www.ncbi.nlm.nih.gov/pubmed/22548646 | List sodium glucose co-transporter-2 (SGLT2) inhibitors that have been FDA approved for type 2 diabetes mellitus treatment. | Canagliflozin, along with dapagliflozin and empagliflozin, are SGLT2 inhibitors approved by the US FDA for use in the treatment of type 2 diabetes. |
http://www.ncbi.nlm.nih.gov/pubmed/8213821,http://www.ncbi.nlm.nih.gov/pubmed/8556817,http://www.ncbi.nlm.nih.gov/pubmed/11479729,http://www.ncbi.nlm.nih.gov/pubmed/16039881,http://www.ncbi.nlm.nih.gov/pubmed/8986634,http://www.ncbi.nlm.nih.gov/pubmed/23936319,http://www.ncbi.nlm.nih.gov/pubmed/20004604,http://www.ncbi.nlm.nih.gov/pubmed/14757438,http://www.ncbi.nlm.nih.gov/pubmed/1899336,http://www.ncbi.nlm.nih.gov/pubmed/10882637,http://www.ncbi.nlm.nih.gov/pubmed/21704274,http://www.ncbi.nlm.nih.gov/pubmed/9733040,http://www.ncbi.nlm.nih.gov/pubmed/9187679,http://www.ncbi.nlm.nih.gov/pubmed/22230121,http://www.ncbi.nlm.nih.gov/pubmed/21223590,http://www.ncbi.nlm.nih.gov/pubmed/8051940,http://www.ncbi.nlm.nih.gov/pubmed/7857677,http://www.ncbi.nlm.nih.gov/pubmed/2464926,http://www.ncbi.nlm.nih.gov/pubmed/17427031,http://www.ncbi.nlm.nih.gov/pubmed/2117855,http://www.ncbi.nlm.nih.gov/pubmed/2349952,http://www.ncbi.nlm.nih.gov/pubmed/9175735,http://www.ncbi.nlm.nih.gov/pubmed/9295080,http://www.ncbi.nlm.nih.gov/pubmed/7923859 | What is the gene mutated in the Gaucher disease? | The glucocerebrosidase gene (GBA) |
http://www.ncbi.nlm.nih.gov/pubmed/17852557,http://www.ncbi.nlm.nih.gov/pubmed/11597323,http://www.ncbi.nlm.nih.gov/pubmed/21590129,http://www.ncbi.nlm.nih.gov/pubmed/20334641,http://www.ncbi.nlm.nih.gov/pubmed/17602063,http://www.ncbi.nlm.nih.gov/pubmed/11984063,http://www.ncbi.nlm.nih.gov/pubmed/8783669,http://www.ncbi.nlm.nih.gov/pubmed/11379297,http://www.ncbi.nlm.nih.gov/pubmed/8976819,http://www.ncbi.nlm.nih.gov/pubmed/19182669,http://www.ncbi.nlm.nih.gov/pubmed/23154884,http://www.ncbi.nlm.nih.gov/pubmed/11712796,http://www.ncbi.nlm.nih.gov/pubmed/14574457 | Why does the prodrug amifostine (ethyol) create hypoxia? | After the administration of Prodrug amifostine the cells of the tissue prefer anaerobic glycolysis rather than regular cellular aerobic respiration. By the beggining of anaerobic glycolysis the inducible by hypoxia proteins are induced and by all these molecules the hypoxic conditions consist of. |
http://www.ncbi.nlm.nih.gov/pubmed/19278965,http://www.ncbi.nlm.nih.gov/pubmed/8374893,http://www.ncbi.nlm.nih.gov/pubmed/22052692,http://www.ncbi.nlm.nih.gov/pubmed/3133104 | What is considered a reliable technique for the definitive cytogenetic diagnosis of Fanconi anemia homozygosity? | In vitro enhancement of chromosome breakage by diepoxybutane (DEB) and mitomycin C (MMC) are reliable techniques for the definitive cytogenetic diagnosis of Fanconi anemia homozygosity.In the great majority of cases, DEB and MMC stressing are reliable techniques for the definitive cytogenetic diagnosis of FA homozygosity |
http://www.ncbi.nlm.nih.gov/pubmed/24250247,http://www.ncbi.nlm.nih.gov/pubmed/24315007,http://www.ncbi.nlm.nih.gov/pubmed/24205503,http://www.ncbi.nlm.nih.gov/pubmed/24101370,http://www.ncbi.nlm.nih.gov/pubmed/24196483,http://www.ncbi.nlm.nih.gov/pubmed/24044569,http://www.ncbi.nlm.nih.gov/pubmed/24060994,http://www.ncbi.nlm.nih.gov/pubmed/24069349,http://www.ncbi.nlm.nih.gov/pubmed/23585095,http://www.ncbi.nlm.nih.gov/pubmed/24058411 | Can exosomes be detected in urine? | Yes, urinary exosomes can be detected in urine. |
http://www.ncbi.nlm.nih.gov/pubmed/19497860,http://www.ncbi.nlm.nih.gov/pubmed/22699452,http://www.ncbi.nlm.nih.gov/pubmed/19736520,http://www.ncbi.nlm.nih.gov/pubmed/22801375,http://www.ncbi.nlm.nih.gov/pubmed/22310283,http://www.ncbi.nlm.nih.gov/pubmed/17707228,http://www.ncbi.nlm.nih.gov/pubmed/24163373,http://www.ncbi.nlm.nih.gov/pubmed/22399799 | What is the role of lysine-specific demethylase 1 (LSD1) in hematopoiesis? | LSD1 represents a central regulator of hematopoietic stem and progenitor cells. LSD1 knockdown (LSD1-kd) expanded progenitor numbers by enhancing their proliferative behavior. LSD1-kd led to an extensive expansion of granulomonocytic, erythroid and megakaryocytic progenitors. In contrast, terminal granulopoiesis, erythropoiesis and platelet production were severely inhibited. The only exception was monopoiesis, which was promoted by LSD1 deficiency. Importantly, we showed that peripheral blood granulocytopenia, monocytosis, anemia and thrombocytopenia were reversible after LSD1-kd termination. Extramedullary splenic hematopoiesis contributed to the phenotypic reversion, and progenitor populations remained expanded. LSD1-kd was associated with the upregulation of key hematopoietic genes, including Gfi1b, Hoxa9 and Meis1, which are known regulators of the HSC/progenitor compartment. We also demonstrated that LSD1-kd abrogated Gfi1b-negative autoregulation by crossing LSD1-kd with Gfi1b:GFP mice. There is also epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b that is mediated by the cofactors CoREST and LSD1. A short Gfi-1B isoform controls erythroid differentiation by recruiting the LSD1-CoREST complex through the dimethylation of its SNAG domain. The enzymatic domain of LSD1 plays an important role in repressing the TAL1-directed transcription of GAL4 reporter linked to a thymidine kniase minimal promoter. Furthermore, the TAL1-associated LSD1, HDAC1, and their enzymatic activities are coordinately down-regulated during the early phases of erythroid differentiation. Consistent with the rapid changes of TAL1-corepressor complex during differentiation, TAL1 recruits LSD1 to the silenced p4.2 promoter in undifferentiated, but not in differentiated, murine erythroleukemia (MEL) cells. ShRNA-mediated knockdown of LSD1 in MEL cells resulted in derepression of the TAL1 target gene accompanied by increasing dimeH3K4 at the promoter region. Thus, it appears that histone lysine demethylase LSD1 may negatively regulate TAL1-mediated transcription and that the dynamic regulation of TAL1-associated LSD1/HDAC1 complex may determine the onset of erythroid differentiation programs. Furthermore, RUNX1 has been shown to be part of a large transcription factor complex, together with LDB1, GATA1, TAL1, and ETO2 in erythroid cells. RUNX1 interacts with LSD1 and MYEF2 in erythroid cells. MYEF2 is bound in undifferentiated cells and is lost upon differentiation, whereas LSD1 is bound in differentiated cells. Finally, LSD1 also participates in the trans-repressive effects of SALL4. Based on luciferase assays, the amine oxidase domain of LSD1 is important in suppressing SALL4-mediated reporter transcription. In freshly isolated adult mouse bone marrows, both SALL4 and LSD1 proteins are preferentially expressed in undifferentiated progenitor cells and co-localize in the nuclei. Further sequential chromatin immunoprecipitation assay confirmed that these two factors share the same binding sites at the promoter regions of important hematopoietic regulatory genes including EBF1, GATA1, and TNF. |
http://www.ncbi.nlm.nih.gov/pubmed/16625511,http://www.ncbi.nlm.nih.gov/pubmed/10440458,http://www.ncbi.nlm.nih.gov/pubmed/16047503,http://www.ncbi.nlm.nih.gov/pubmed/11533860,http://www.ncbi.nlm.nih.gov/pubmed/7952245,http://www.ncbi.nlm.nih.gov/pubmed/1618284,http://www.ncbi.nlm.nih.gov/pubmed/8891947,http://www.ncbi.nlm.nih.gov/pubmed/12596031,http://www.ncbi.nlm.nih.gov/pubmed/10746298,http://www.ncbi.nlm.nih.gov/pubmed/9384923,http://www.ncbi.nlm.nih.gov/pubmed/17347940,http://www.ncbi.nlm.nih.gov/pubmed/10320209 | For the treatment of which conditions can atypical neuroleptic drugs be used? | Atypical neuroloeptic drugs are antipsychotics used in patients with schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders, psychotic relapse in neuroleptic malignant syndrome and attention deficit hyperactivity disorder when presenting with negativism and conduct disorder. |
http://www.ncbi.nlm.nih.gov/pubmed/12689820,http://www.ncbi.nlm.nih.gov/pubmed/15176430,http://www.ncbi.nlm.nih.gov/pubmed/20306271,http://www.ncbi.nlm.nih.gov/pubmed/15831539,http://www.ncbi.nlm.nih.gov/pubmed/22589293,http://www.ncbi.nlm.nih.gov/pubmed/17119796,http://www.ncbi.nlm.nih.gov/pubmed/12148092,http://www.ncbi.nlm.nih.gov/pubmed/17395133,http://www.ncbi.nlm.nih.gov/pubmed/16571646,http://www.ncbi.nlm.nih.gov/pubmed/17272325,http://www.ncbi.nlm.nih.gov/pubmed/16859779,http://www.ncbi.nlm.nih.gov/pubmed/12032359,http://www.ncbi.nlm.nih.gov/pubmed/20609799,http://www.ncbi.nlm.nih.gov/pubmed/10406668,http://www.ncbi.nlm.nih.gov/pubmed/16769944,http://www.ncbi.nlm.nih.gov/pubmed/17399643,http://www.ncbi.nlm.nih.gov/pubmed/20382953,http://www.ncbi.nlm.nih.gov/pubmed/12536108,http://www.ncbi.nlm.nih.gov/pubmed/12909315,http://www.ncbi.nlm.nih.gov/pubmed/19445372,http://www.ncbi.nlm.nih.gov/pubmed/8080508,http://www.ncbi.nlm.nih.gov/pubmed/16877549,http://www.ncbi.nlm.nih.gov/pubmed/23644778,http://www.ncbi.nlm.nih.gov/pubmed/10190827,http://www.ncbi.nlm.nih.gov/pubmed/15269659,http://www.ncbi.nlm.nih.gov/pubmed/18554214,http://www.ncbi.nlm.nih.gov/pubmed/21317470,http://www.ncbi.nlm.nih.gov/pubmed/17582433,http://www.ncbi.nlm.nih.gov/pubmed/19570891 | Which are the characteristics of Andersen syndrome? | the characteristics of Andersen syndrome are abnormal QT-U complex, ventricular arrhythmia, periodic paralysis, and facial and skeletal dysmorphisms |
http://www.ncbi.nlm.nih.gov/pubmed/21919874,http://www.ncbi.nlm.nih.gov/pubmed/23229562,http://www.ncbi.nlm.nih.gov/pubmed/22917225,http://www.ncbi.nlm.nih.gov/pubmed/21569778,http://www.ncbi.nlm.nih.gov/pubmed/23896987,http://www.ncbi.nlm.nih.gov/pubmed/22447279,http://www.ncbi.nlm.nih.gov/pubmed/23390563,http://www.ncbi.nlm.nih.gov/pubmed/21527744,http://www.ncbi.nlm.nih.gov/pubmed/23819949,http://www.ncbi.nlm.nih.gov/pubmed/21451408,http://www.ncbi.nlm.nih.gov/pubmed/22385148,http://www.ncbi.nlm.nih.gov/pubmed/23292032,http://www.ncbi.nlm.nih.gov/pubmed/23955788,http://www.ncbi.nlm.nih.gov/pubmed/24298311 | How are induced pluripotent stem cells used in the study and treatment of cardiovascular diseases? | The major goal within the field of cardiovascular regenerative medicine is to replace lost or damaged cardiac muscle and coronaries following ischaemic disease. At present, de novo cardiomyocytes can be generated either in vitro, using directed differentiation of embryonic stem cells or induced pluripotent stem cells, or in vivo via direct reprogramming of resident adult cardiac fibroblast or ectopic stimulation of resident cardiac stem or progenitor cells. The production of human cardiac progenitor cells and cardiomyocytes from human pluripotent stem cells provides an amenable source of cells for applications in drug discovery, disease modeling, regenerative medicine, and cardiotoxicity screening. In addition, the ability to derive human-induced pluripotent stem cells from somatic tissues, combined with current high-throughput screening and pharmacogenomics, may help realize the use of these cells to fulfill the potential of personalized medicine. Human induced pluripotent stem cells (iPSC) provide a unique opportunity to study "disease in a dish" within a defined genetic and environmental background. Patient-derived iPSCs have been successfully used to model cardiomyopathies, rhythm disorders and vascular disorders. Long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia are two heart rhythm disorders that have been already successfully modeled by several groups using this approach, which will likely serve to model other mono- or polygenetic cardiovascular disorders in the future. The use of iPSC-derived cardiomyocytes to study genetic cardiovascular disorders will enable a deeper and more applicable understanding of the molecular mechanisms of human disease, as well as improving our ability to achieve successful cell-based therapies. |
http://www.ncbi.nlm.nih.gov/pubmed/12878302,http://www.ncbi.nlm.nih.gov/pubmed/7573130,http://www.ncbi.nlm.nih.gov/pubmed/7573131,http://www.ncbi.nlm.nih.gov/pubmed/18192286,http://www.ncbi.nlm.nih.gov/pubmed/23023332,http://www.ncbi.nlm.nih.gov/pubmed/1785632,http://www.ncbi.nlm.nih.gov/pubmed/23427148,http://www.ncbi.nlm.nih.gov/pubmed/8563763,http://www.ncbi.nlm.nih.gov/pubmed/12846610,http://www.ncbi.nlm.nih.gov/pubmed/23984569,http://www.ncbi.nlm.nih.gov/pubmed/22639450,http://www.ncbi.nlm.nih.gov/pubmed/21307714,http://www.ncbi.nlm.nih.gov/pubmed/17303258,http://www.ncbi.nlm.nih.gov/pubmed/10874640,http://www.ncbi.nlm.nih.gov/pubmed/20621975,http://www.ncbi.nlm.nih.gov/pubmed/9130129,http://www.ncbi.nlm.nih.gov/pubmed/9571278,http://www.ncbi.nlm.nih.gov/pubmed/20301454,http://www.ncbi.nlm.nih.gov/pubmed/8929375,http://www.ncbi.nlm.nih.gov/pubmed/16760737,http://www.ncbi.nlm.nih.gov/pubmed/15883926,http://www.ncbi.nlm.nih.gov/pubmed/9508238,http://www.ncbi.nlm.nih.gov/pubmed/17979970,http://www.ncbi.nlm.nih.gov/pubmed/7605558,http://www.ncbi.nlm.nih.gov/pubmed/15884042,http://www.ncbi.nlm.nih.gov/pubmed/16970241 | Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome? | Shprintzen-Goldberg syndrome (SGS) is characterized by: craniosynostosis of the coronal, sagittal, or lambdoid sutures; dolichocephaly; distinctive craniofacial features; skeletal changes (dolichostenomelia, arachnodactyly, camptodactyly, pes planus, pectus excavatum or carinatum, scoliosis, joint hypermobility or contractures and C1/C2 spine malformation); neurologic abnormalities; intellectual disability; and brain anomalies (hydrocephalus, dilatation of the lateral ventricles, and Chiari 1 malformation). Cardiovascular anomalies may include mitral valve prolapse, mitral regurgitation/incompetence, aortic regurgitation and aortic root dilatation. Minimal subcutaneous fat, abdominal wall defects, myopia, and cryptorchidism in males, are also characteristic findings.Shprintzen-Goldberg syndrome (SGS) is characterized by craniosynostosis and marfanoid habitus.Hirschsprung disease is very often identified as an additional feature of the Goldberg-Shprintzen syndrome.Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndromeMutations in Kif1-binding protein/KIAA1279 (KBP) cause the devastating neurological disorder Goldberg-Shprintzen syndrome (GSS) in humans.Shprintzen-Goldberg syndrome (SGS) is characterized by: craniosynostosis of the coronal, sagittal, or lambdoid sutures; dolichocephaly; distinctive craniofacial features; skeletal changes (dolichostenomelia, arachnodactyly, camptodactyly, pes planus, pectus excavatum or carinatum, scoliosis, joint hypermobility or contractures and C1/C2 spine malformation); neurologic abnormalities; intellectual disability; and brain anomalies (hydrocephalus, dilatation of the lateral ventricles, and Chiari 1 malformation). Cardiovascular anomalies may include mitral valve prolapse, mitral regurgitation/incompetence, aortic regurgitation and aortic root dilatation. Minimal subcutaneous fat, abdominal wall defects, myopia, and cryptorchidism in males, are also characteristic findings.
The Shprintzen-Goldberg syndrome is an extremely rare syndrome with a characteristic face. This is one of a group of disorders characterized by craniosynostosis and marfanoid features. |
http://www.ncbi.nlm.nih.gov/pubmed/23344365,http://www.ncbi.nlm.nih.gov/pubmed/24015757,http://www.ncbi.nlm.nih.gov/pubmed/24292773,http://www.ncbi.nlm.nih.gov/pubmed/21697885,http://www.ncbi.nlm.nih.gov/pubmed/21895535,http://www.ncbi.nlm.nih.gov/pubmed/24138501,http://www.ncbi.nlm.nih.gov/pubmed/23347305,http://www.ncbi.nlm.nih.gov/pubmed/23407075,http://www.ncbi.nlm.nih.gov/pubmed/24211642,http://www.ncbi.nlm.nih.gov/pubmed/20657595 | Which protein is causing Netherton syndrome? | Netherton syndrome (NS) is a serious inherited skin disorder caused by mutations in the gene SPINK5 (serine protease inhibitor Kazal type 5) which encodes for a serine protease inhibitor LEKTI (lymphoepithelial Kazal type-related inhibitor) |
http://www.ncbi.nlm.nih.gov/pubmed/22377713,http://www.ncbi.nlm.nih.gov/pubmed/17608759,http://www.ncbi.nlm.nih.gov/pubmed/10835624,http://www.ncbi.nlm.nih.gov/pubmed/19438860,http://www.ncbi.nlm.nih.gov/pubmed/11841556,http://www.ncbi.nlm.nih.gov/pubmed/16307658,http://www.ncbi.nlm.nih.gov/pubmed/20877344,http://www.ncbi.nlm.nih.gov/pubmed/17989726,http://www.ncbi.nlm.nih.gov/pubmed/21251800,http://www.ncbi.nlm.nih.gov/pubmed/11511292,http://www.ncbi.nlm.nih.gov/pubmed/21255986,http://www.ncbi.nlm.nih.gov/pubmed/23407075,http://www.ncbi.nlm.nih.gov/pubmed/15304086,http://www.ncbi.nlm.nih.gov/pubmed/16225619,http://www.ncbi.nlm.nih.gov/pubmed/24015757,http://www.ncbi.nlm.nih.gov/pubmed/16796630 | Mutations in which gene and which protein are associated with Netherton syndrome? | NS is due to loss-of-function mutations in the SPINK5 gene and to the consequent lack of expression of its encoded protein LEKTI in the skin and all stratified epithelial tissues. |
http://www.ncbi.nlm.nih.gov/pubmed/2085926,http://www.ncbi.nlm.nih.gov/pubmed/22355263,http://www.ncbi.nlm.nih.gov/pubmed/22251432,http://www.ncbi.nlm.nih.gov/pubmed/25514659,http://www.ncbi.nlm.nih.gov/pubmed/23281786,http://www.ncbi.nlm.nih.gov/pubmed/23979994,http://www.ncbi.nlm.nih.gov/pubmed/23587141,http://www.ncbi.nlm.nih.gov/pubmed/24465140,http://www.ncbi.nlm.nih.gov/pubmed/10986355,http://www.ncbi.nlm.nih.gov/pubmed/23225525,http://www.ncbi.nlm.nih.gov/pubmed/24291999,http://www.ncbi.nlm.nih.gov/pubmed/19877240,http://www.ncbi.nlm.nih.gov/pubmed/20174468,http://www.ncbi.nlm.nih.gov/pubmed/19155272,http://www.ncbi.nlm.nih.gov/pubmed/23531432,http://www.ncbi.nlm.nih.gov/pubmed/1534893,http://www.ncbi.nlm.nih.gov/pubmed/24095115 | Which disease of the central nervous system is characterized by the presence of Lewy bodies? | Parkinson s disease (PD) is one of the most common degenerative disorders of the central nervous system that produces motor and non-motor symptoms. The majority of cases are idiopathic and characterized by the presence of Lewy bodies containing fibrillar α-synuclein Parkinson's disease (PD) is one of the most common degenerative disorders of the central nervous system that produces motor and non-motor symptoms. The majority of cases are idiopathic and characterized by the presence of Lewy bodies containing fibrillar α-synuclein.Parkinsons disease (PD) is one of the most common degenerative disorders of the central nervous system that produces motor and non-motor symptoms. The protein α-synuclein is well recognized to contribute to the pathogenesis of Parkinson disease and is the major component of Lewy bodies and Lewy neurites |
http://www.ncbi.nlm.nih.gov/pubmed/9389494,http://www.ncbi.nlm.nih.gov/pubmed/9794474,http://www.ncbi.nlm.nih.gov/pubmed/8550759,http://www.ncbi.nlm.nih.gov/pubmed/9709961,http://www.ncbi.nlm.nih.gov/pubmed/7629231,http://www.ncbi.nlm.nih.gov/pubmed/15072569 | Which deiodinase is known to be present in liver? | High D1 and D3 activities are present in fetal human liver, and high D1 and mostly absent D3 activities are present in adult human liver. |
http://www.ncbi.nlm.nih.gov/pubmed/20972443,http://www.ncbi.nlm.nih.gov/pubmed/18758478,http://www.ncbi.nlm.nih.gov/pubmed/11536431,http://www.ncbi.nlm.nih.gov/pubmed/20118921,http://www.ncbi.nlm.nih.gov/pubmed/21124806,http://www.ncbi.nlm.nih.gov/pubmed/12644465,http://www.ncbi.nlm.nih.gov/pubmed/12205678,http://www.ncbi.nlm.nih.gov/pubmed/21245387,http://www.ncbi.nlm.nih.gov/pubmed/16530044,http://www.ncbi.nlm.nih.gov/pubmed/22325781 | Which proteins participate in the formation of the Notch transcriptional activation complex? | The Notch intracellular domain (NICD) forms a transcriptional activation complex with the DNA-binding factor CSL and a transcriptional co-activator of the Mastermind family (MAML). ICN binds to a highly conserved DNA-binding transcription factor called CSL (also known as RBP-Jkappa, CBF1, Suppressor of Hairless, and Lag-1) and recruits Mastermind-like transcriptional co-activators to form a transcriptional activation complex.Although it is well understood that N(ICD) forms a transcriptional activation complex, little is known about how the complex is assembled. The Notch intracellular domain (NICD) forms a transcriptional activation complex with the DNA-binding factor CSL and a transcriptional co-activator of the Mastermind family (MAML). |
http://www.ncbi.nlm.nih.gov/pubmed/12072528,http://www.ncbi.nlm.nih.gov/pubmed/20421997,http://www.ncbi.nlm.nih.gov/pubmed/9783696,http://www.ncbi.nlm.nih.gov/pubmed/11292724,http://www.ncbi.nlm.nih.gov/pubmed/22661385,http://www.ncbi.nlm.nih.gov/pubmed/17258731,http://www.ncbi.nlm.nih.gov/pubmed/22863657,http://www.ncbi.nlm.nih.gov/pubmed/22067045,http://www.ncbi.nlm.nih.gov/pubmed/12547627,http://www.ncbi.nlm.nih.gov/pubmed/18721481,http://www.ncbi.nlm.nih.gov/pubmed/11790764,http://www.ncbi.nlm.nih.gov/pubmed/8944774,http://www.ncbi.nlm.nih.gov/pubmed/16609350,http://www.ncbi.nlm.nih.gov/pubmed/7511773,http://www.ncbi.nlm.nih.gov/pubmed/16517887,http://www.ncbi.nlm.nih.gov/pubmed/17353288,http://www.ncbi.nlm.nih.gov/pubmed/15613860 | How is the sequence variability defined in antibodies? | The variability at each position of the polypeptide chain is defined as:
Variability = number of different amino acids at a given position / frequency of the most common amino acid at given position. |